

Welcome to STN International! Enter x:x

LOGINID:sssptal611sxp

PASSWORD:

* * * * * RECONNECTED TO STN INTERNATIONAL * * * * *

SESSION RESUMED IN FILE 'HOME' AT 13:18:23 ON 30 JUN 2003

FILE 'HOME' ENTERED AT 13:18:23 ON 30 JUN 2003

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.63	0.63

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.63	0.63

FILE 'REGISTRY' ENTERED AT 13:18:37 ON 30 JUN 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 29 JUN 2003 HIGHEST RN 539790-82-4

DICTIONARY FILE UPDATES: 29 JUN 2003 HIGHEST RN 539790-82-4

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:

<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=>


Uploading 10046526.1

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 13:19:04 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 7 TO ITERATE

100.0% PROCESSED 7 ITERATIONS
SEARCH TIME: 00.00.01

0 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 7 TO 298
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 sss full

FULL SEARCH INITIATED 13:19:12 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 85 TO ITERATE

100.0% PROCESSED 85 ITERATIONS
SEARCH TIME: 00.00.01

1 ANSWERS

L3 1 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS

SINCE FILE TOTAL
ENTRY SESSION

FULL ESTIMATED COST

148.15

148.78

FILE 'CAPLUS' ENTERED AT 13:19:17 ON 30 JUN 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 30 Jun 2003 VOL 139 ISS 1
FILE LAST UPDATED: 29 Jun 2003 (20030629/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 13

L4 1 L3

=> d l4 fbib hitstr abs total

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS

AN 2002:539663 CAPLUS

DN 137:109210

TI Preparation of substituted arylamine derivatives and methods of use as antitumor agents

IN Chen, Guoging; Booker, Shon; Cai, Guolin; Croghan, Michael; Dipietro, Lucian; Dominguez, Celia; Elbaum, Daniel; Germain, Julie; Huang, Qi; Kim, Joseph L.; Kim, Tae-Seong; Patel, Vinod F.; Smith, Leon M.; Tasker, Andrew; Xi, Ning; Xu, Shimin; Yuan, Chester Chenguang

PA Amgen Inc., USA

SO PCT Int. Appl., 253 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002055501	A2	20020718	WO 2002-US742	20020111
	WO 2002055501	A3	20021219		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

Patel

<6/30/2003>

US 2002147198 A1 20021010

US 2001-261360PP 20010112

US 2001-323686PP 20010919

US 2002-46526 A 20020110

US 2002-46526 20020110

US 2001-261360PP 20010112

US 2001-323686PP 20010919

SBP
SBP

OS MARPAT 137:109210


IT 442846-35-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(target compd.; prepn. of substituted aminopyridines as antitumor agents)

RN 442846-35-7 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[[(4-fluorophenyl)methyl]amino]-N-[4-[1-methyl-1-(1-methyl-4-piperidinyl)ethyl]phenyl]]- (9CI) (CA INDEX NAME)



Specimen

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [B1 and B2 independently equal C or N, wherein B1B2 form part of 5-6 membered heteroaryl ring A; R1 = one or more substituents selected from H, halo, oxo, (un)substituted cycloalkyl, phenylalkyl, etc.; R2 = (un)substituted cycloalkyl, cycloalkenyl, 6-10 membered aryl or 5-6 membered heterocyclyl, etc.; R3 = (un)substituted aryl; R4 = H, alkyl, (un)substituted Ph or aralkyl; X1 = bond, alkylene, alkenylene and alkynylene, where one of the CH2 groups may be substituted with O or NH, wherein X1 is optionally substituted with OH; X2 = (un)substituted N contg. linker, e.g., -NHCH2-, and there pharmaceutically acceptable derivs., are prepd. and disclosed as agents effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. Thus, II was prepd. via arylation of 1-dimethylamino-2-propyne with 3-bromo-5-trifluoromethylaniline, hydrogenation, amidation with 2-chloropyridine-3-carbonyl chloride and chloro-substitution with 4-phenoxyaniline. Selected compds. of the invention, e.g., II, inhibited

VEGF-stimulated cell proliferation at a level below 50 nM. The invention encompasses novel compds., analogs, prodrugs and pharmaceutically acceptable derivs. thereof, pharmaceutical compns. and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like.

=> d cost

COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
CONNECT CHARGES	0.34	1.13
NETWORK CHARGES	0.06	0.30
SEARCH CHARGES	0.00	147.75
DISPLAY CHARGES	4.32	4.32

CAPLUS FEE (5%)

4.72 153.50

0.23 0.23

FULL ESTIMATED COST

4.95 153.73

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE TOTAL

ENTRY SESSION

CA SUBSCRIBER PRICE

-0.65 -0.65

IN FILE 'CAPLUS' AT 13:19:53 ON 30 JUN 2003

Welcome to STN International! Enter x:x

LOGINID:sssptal611sxp

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	Jun 03	New e-mail delivery for search results now available
NEWS	4	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS	5	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS	6	Aug 26	Sequence searching in REGISTRY enhanced
NEWS	7	Sep 03	JAPIO has been reloaded and enhanced
NEWS	8	Sep 16	Experimental properties added to the REGISTRY file
NEWS	9	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS	10	Oct 01	CASREACT Enriched with Reactions from 1907 to 1985
NEWS	11	Oct 24	BEILSTEIN adds new search fields
NEWS	12	Oct 24	Nutraceuticals International (NUTRACEUT) now available on STN
NEWS	13	Nov 18	DKILIT has been renamed APOLLIT
NEWS	14	Nov 25	More calculated properties added to REGISTRY
NEWS	15	Dec 04	CSA files on STN
NEWS	16	Dec 17	PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS	17	Dec 17	TOXCENTER enhanced with additional content
NEWS	18	Dec 17	Adis Clinical Trials Insight now available on STN
NEWS	19	Jan 29	Simultaneous left and right truncation added to COMPENDEX, ENERGY, INSPEC
NEWS	20	Feb 13	CANCERLIT is no longer being updated
NEWS	21	Feb 24	METADEX enhancements
NEWS	22	Feb 24	PCTGEN now available on STN
NEWS	23	Feb 24	TEMA now available on STN
NEWS	24	Feb 26	NTIS now allows simultaneous left and right truncation
NEWS	25	Feb 26	PCTFULL now contains images
NEWS	26	Mar 04	SDI PACKAGE for monthly delivery of multifile SDI results
NEWS	27	Mar 20	EVENTLINE will be removed from STN
NEWS	28	Mar 24	PATDPAFULL now available on STN
NEWS	29	Mar 24	Additional information for trade-named substances without structures available in REGISTRY
NEWS	30	Apr 11	Display formats in DGENE enhanced
NEWS	31	Apr 14	MEDLINE Reload
NEWS	32	Apr 17	Polymer searching in REGISTRY enhanced
NEWS	33	Jun 13	Indexing from 1947 to 1956 added to records in CA/CAPLUS
NEWS	34	Apr 21	New current-awareness alert (SDI) frequency in WPIDS/WPINDEX/WPIX
NEWS	35	Apr 28	RDISCLOSURE now available on STN
NEWS	36	May 05	Pharmacokinetic information and systematic chemical names added to PHAR
NEWS	37	May 15	MEDLINE file segment of TOXCENTER reloaded
NEWS	38	May 15	Supporter information for ENCOMPPAT and ENCOMPLIT updated
NEWS	39	May 16	CHEMREACT will be removed from STN
NEWS	40	May 19	Simultaneous left and right truncation added to WSCA

NEWS 41 May 19 RAPRA enhanced with new search field, simultaneous left and right truncation
 NEWS 42 Jun 06 Simultaneous left and right truncation added to CBNB
 NEWS 43 Jun 06 PASCAL enhanced with additional data
 NEWS 44 Jun 20 2003 edition of the FSTA Thesaurus is now available
 NEWS 45 Jun 25 HSDB has been reloaded

NEWS EXPRESS April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
 NEWS HOURS STN Operating Hours Plus Help Desk Availability
 NEWS INTER General Internet Information
 NEWS LOGIN Welcome Banner and News Items
 NEWS PHONE Direct Dial and Telecommunication Network Access to STN
 NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 13:25:55 ON 30 JUN 2003

=> file reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 13:26:04 ON 30 JUN 2003
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 29 JUN 2003 HIGHEST RN 539790-82-4
 DICTIONARY FILE UPDATES: 29 JUN 2003 HIGHEST RN 539790-82-4

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=>


Uploading 10046526.2

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 Cb,Cy,Hy,Ak

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 13:26:26 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 2066 TO ITERATE

48.4% PROCESSED 1000 ITERATIONS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

10 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 38594 TO 44046

PROJECTED ANSWERS: 141 TO 685

L2 10 SEA SSS SAM L1

=> s l1 sss full

FULL SEARCH INITIATED 13:26:33 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 40731 TO ITERATE

100.0% PROCESSED 40731 ITERATIONS
SEARCH TIME: 00.00.02

255 ANSWERS

L3 255 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS
FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
148.15	148.36

FILE 'CAPLUS' ENTERED AT 13:26:41 ON 30 JUN 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 30 Jun 2003 VOL 139 ISS 1
FILE LAST UPDATED: 29 Jun 2003 (20030629/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 13

L4 20 L3

=> d 14 fbib hitstr abs total

L4 ANSWER 1 OF 20 CAPLUS COPYRIGHT 2003 ACS
AN 2003:319701 CAPLUS
DN 138:337840
TI Preparation of 5'-acylamino-1,1'-biphenyl-4-carboxamides as p38 kinase inhibitors
IN Angell, Richard Martyn; Aston, Nicola Mary; Bamborough, Paul; Bamford, Mark James; Cockerill, George Stuart; Flack, Stephen Sean; Laine, Dramane Ibrahim; Merrick, Suzanne Joy; Smith, Kathryn Jane; Walker, Ann Louise
PA Glaxo Group Limited, UK
SO PCT Int. Appl., 64 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003032971	A1	20030424	WO 2002-EP11576	20021016
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD,
 RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
 CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
 PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
 NE, SN, TD, TG

GB 2001-24939 A 20011017

OS MARPAT 138:337840

IT 515812-31-4P 515812-32-5P 515812-34-7P


515812-35-8P 515812-44-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(prepn. of 5'-acylamino-1,1'-biphenyl-4-carboxamides as p38 kinase
 inhibitors)


RN 515812-31-4 CAPLUS

CN 4-Pyridinecarboxamide, 2-[(cyclopropylmethyl)amino]-N-[4'-
 [[[(cyclopropylmethyl)amino]carbonyl]-6-methyl[1,1'-biphenyl]-3-yl]- (9CI)
 (CA INDEX NAME)




RN 515812-32-5 CAPLUS

CN 4-Pyridinecarboxamide, N-[4'-[[[(cyclopropylmethyl)amino]carbonyl]-6-
 methyl[1,1'-biphenyl]-3-yl]-2-[(2-methylpropyl)amino]- (9CI) (CA INDEX
 NAME)




RN 515812-34-7 CAPLUS

CN 4-Pyridinecarboxamide, 2-(cyclohexylamino)-N-[4'-
 [[[(cyclopropylmethyl)amino]carbonyl]-6-methyl[1,1'-biphenyl]-3-yl]- (9CI)
 (CA INDEX NAME)




RN 515812-35-8 CAPLUS

CN 4-Pyridinecarboxamide, 2-(cyclopropylamino)-N-[4'-
[[(cyclopropylmethyl) amino] carbonyl] -6-methyl [1,1'-biphenyl]-3-yl] - (9CI)
(CA INDEX NAME)




RN 515812-44-9 CAPLUS

CN 4-Pyridinecarboxamide, 2-(cyclobutylamino)-N-[4'-
[[(cyclopropylmethyl) amino] carbonyl] -6-methyl [1,1'-biphenyl]-3-yl] - (9CI)
(CA INDEX NAME)



GI



AB The title compds. [I; when m = 0-4, R¹ = alkyl, cycloalkyl, alkenyl, etc.; when m = 2-4, R¹ addnl. = alkoxy, OH, etc.; R² = H, alkyl, (CH₂)_ncycloalkyl; R³ = NHCOR₆ (wherein R₆ = H, alkyl, alkoxy, etc.); U = Me, halo; W = Me, Cl; X, Y = H, Me, halo; m = 0-4; n = 0-1; s = 0-2], useful as pharmaceuticals, particularly as p38 kinase inhibitors, were prepd. E.g., a 6-step synthesis of the nicotinamide II, starting with 3-bromo-4-methylaniline, was given.

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE.FORMAT

L4 ANSWER 2 OF 20 CAPLUS COPYRIGHT 2003 ACS

AN 2003:261670 CAPLUS

DN 138:287666

TI Preparation of heteroaryllactams as Factor Xa inhibitors

IN Pinto, Donald; Quan, Mimi; Orwat, Michael; Li, Yun-Long; Han, Wei; Qiao, Jennifer; Lam, Patrick; Koch, Stephanie

PA Bristol-Myers Squibb Company, USA

SO PCT Int. Appl., 441 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003026652	A1	20030403	WO 2002-US29491	20020917
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

US 2001-324165PP 20010921

OS MARPAT 138:287666


IT 503613-25-0P, 2-[(4-Chlorobenzoyl)amino]-N-[4-(2-oxo-1-piperidinyl)phenyl]nicotinamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(claimed compd.; prepn. of heteroaryllactams as Factor Xa inhibitors)

RN 503613-25-0 CAPLUS

CN 3-Pyridinecarboxamide, 2-[(4-chlorobenzoyl)amino]-N-[4-(2-oxo-1-piperidinyl)phenyl]- (9CI) (CA INDEX NAME)



AB P4PMM4 [M = 3-10 membered (substituted) (unsatd.) carbocyclyl, 4-10 membered heterocyclyl; P = null, 5-7 membered (substituted) (unsatd.) carbocyclyl, heterocyclyl fused to ring M; 1 of P4, M4 = ZAB, the other = GlG; G = (benzo-, pyrido-, pyrimido-, pyrazino-, or pyridazino-fused) (substituted) (unsatd.) 5-6 membered (hetero)cyclyl; Gl = null, (CR3R3a)1-5, etc.; R3, R3a = H, Me, Et, Pr, Ph, PhCH2, etc.; Z = bond, (CR3R3e)1-4, etc.; R3e = H, SO2NHR3, SO2N(R3)2, COR3, (substituted) alkyl, alkenyl, alkynyl, etc.; A = (substituted) 3-10 membered carbocyclyl, 5-12 membered heterocyclyl; Z = XNQ; X = null, CO, SO, SO2, etc.; NQ = 4-8 membered mono- or bicyclic (substituted) (unsatd.) ring contg. a CO or SO2 group adjacent to the N atom; with provisos], were prepd. Thus, 6-(4-iodophenyl)-3-methoxy-1-(4-methoxyphenyl)-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one (prepn. given), .delta.-valerolactam, K2CO3, and CuI were refluxed in Me2SO to give 15% 3-methoxy-1-(4-methoxyphenyl)-6-[4-(2-oxo-1-piperidinyl)phenyl]-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one. Several title compds. inhibited Factor Xa with IC50.1toreq. 10 .mu.M.

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 20 CAPLUS COPYRIGHT 2003 ACS

AN 2003:22869 CAPLUS

DN 138:89806

TI Preparation of arylpyrazoles as soluble epoxide hydrolase inhibitors for treatment of cardiovascular disease.

IN Ingraham, Richard H.; Proudfoot, John R.

PA Boehringer Ingelheim Pharmaceuticals Inc., USA

SO PCT Int. Appl., 44 pp.

CODEN: PIXXD2

DT Patent

LA English


FAN.CNT 1

PATENT NO.


KIND DATE


APPLICATION NO. DATE

 PI WO 2003002555 A1 20030109 WO 2002-US18752 20020614
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 US 2001-302066PP 20010629
 US 2002-172457 20020614
 US 2001-302066PP 20010629
 OS MARPAT 138:89806
 IT **251656-70-9P 251656-71-0P 483342-21-8P**
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (prepn. of arylpyrazoles as sol. epoxide hydrolase inhibitors for
 treatment of cardiovascular disease)
 RN 251656-70-9 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[(5-hydroxypentyl)amino]-N-[4-[3-(3-pyridinyl)-5-
 (trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 251656-71-0 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[2-(4-morpholinyl)ethyl]amino]-N-[4-[3-(3-
 pyridinyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX
 NAME)





RN 483342-21-8 CAPLUS

CN 3-Pyridinecarboxamide, 2-[(phenylmethyl)amino]-N-[4-[3-(3-pyridinyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




IT 251656-99-2


RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(prepn. of arylpyrazoles as sol. epoxide hydrolase inhibitors for
treatment of cardiovascular disease)

RN 251656-99-2 CAPLUS

CN 4-Pyridinecarboxamide, 2-[(2-hydroxyethyl)amino]-N-[4-[3-(3-pyridinyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



GI



AB A method of treating cardiovascular disease comprises administration of title compds. [I; R1, R3 = CF3, halo, cyano, alkyl, alkenyl, alkynyl, (substituted) cycloalkyl, heterocyclyl, etc.; R2 = H, halo, Me; L = NHCO, NHCS, NH, NHCH2, NHCOCO, etc.; R4 = (substituted) alkyl, alkoxy, alkylthio, alkylamino, alkoxyalkyl, alkylthioalkyl, carbocyclyl, heterocyclyl, etc.; R8 = H, NH2] (no data). Thus, 2-chloronicotinic acid in MeCN was treated with EDC and then with 1-(4-aminophenyl)-3-(3-pyridyl)-5-trifluoromethylpyrazole under ice cooling followed by stirring for 1 h to give I (R1 = 3-pyridyl; R2, R8 = H; R3 = CF3; L = NHCO; R4 = 2-chloropyridin-3-yl).

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 20 CAPLUS COPYRIGHT 2003 ACS

AN 2002:676007 CAPLUS

DN 137:216945

TI Preparation of substituted 2-(1H-indazol-6-ylamino)nicotinamides for treating KDR-related diseases

IN Chen, Guoqing; Adams, Jeffrey; Bemis, Jean; Croghan, Michael; Dipietro, Lucian; Dominguez, Celia; Elbaum, Daniel; Germain, Julie; Huang, Qi; Kim, Joseph L.; Ouyang, Xiaohu; Patel, Vinod F.; Smith, Leon M.; Tasker, Andrew; Xi, Ning; Xu, Shimin; Yuan, Chester Chenguang; Kim, Tae-Seong

PA Amgen Inc., USA

SO PCT Int. Appl., 395 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002068406	A2	20020906	WO 2002-US3064	20020111
	WO 2002068406	A3	20030424		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2001-261882PP 20010112				
	US 2001-323808PP 20010919				
	US 2002-46622 A 20020110				

OS MARPAT 137:216945


IT 454480-74-1P 454481-80-2P 454481-82-4P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(prepn. of substituted 2-(1H-indazol-6-ylamino)nicotinamides for treating KDR-related diseases)


RN 454480-74-1 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)phenyl]-2-(1H-indazol-6-ylamino)- (9CI) (CA INDEX NAME)




RN 454481-80-2 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-nitrophenyl]-2-(1H-indazol-6-ylamino)- (9CI) (CA INDEX NAME)



RN 454481-82-4 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-[(2-hydroxyethyl)amino]phenyl]-2-(1H-indazol-6-ylamino)- (9CI) (CA INDEX NAME)




IT 454480-71-8P 454480-73-0P 454480-77-4P
 454480-81-0P 454480-86-5P 454480-87-6P
 454480-88-7P 454480-89-8P 454480-90-1P
 454480-95-6P 454480-97-8P 454480-98-9P
 454481-00-6P 454481-07-3P 454481-12-0P
 454481-17-5P 454481-20-0P 454481-21-1P
 454481-22-2P 454481-23-3P 454481-24-4P
 454481-26-6P 454481-28-8P 454481-30-2P
 454481-31-3P 454481-32-4P 454481-33-5P
 454481-34-6P 454481-35-7P 454481-45-9P
 454481-46-0P 454481-47-1P 454481-48-2P
 454481-49-3P 454481-50-6P 454481-51-7P
 454481-52-8P 454481-53-9P 454481-55-1P
 454481-60-8P 454481-62-0P 454481-63-1P
 454481-65-3P 454481-69-7P 454481-70-0P
 454481-75-5P 454481-76-6P 454481-77-7P
 454481-78-8P 454481-79-9P 454481-83-5P
 454481-84-6P 454481-89-1P 454481-90-4P
 454481-99-3P 454482-04-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of substituted 2-(1H-indazol-6-ylamino)nicotinamides for treating KDR-related diseases)


RN 454480-71-8 CAPLUS

CN 3-Pyridinecarboxamide, 2-(1H-indazol-6-ylamino)-N-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 454480-73-0 CAPLUS


CN 3-Pyridinecarboxamide, 2-(1H-indazol-6-ylamino)-N-[4-(1-methylpropyl)phenyl]- (9CI) (CA INDEX NAME)



RN 454480-77-4 CAPLUS


CN 3-Pyridinecarboxamide, 2-(1H-benzotriazol-5-ylamino)-N-[4-(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)






RN 454480-81-0 CAPLUS

CN 3-Pyridinecarboxamide, 2-[(1,2-dihydro-4-methyl-2-oxo-7-quinolinyl)amino]-N-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 454480-86-5 CAPLUS

CN 3-Pyridinecarboxamide, 2-(1H-indazol-6-ylamino)-N-[4-(nonafluorobutyl)phenyl]- (9CI) (CA INDEX NAME)




RN 454480-87-6 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1-methylethyl)phenyl]-2-[(1-methyl-1H-indazol-6-yl)amino]- (9CI) (CA INDEX NAME)




RN 454480-88-7 CAPLUS

CN 3-Pyridinecarboxamide, 2-[(7-bromo-1H-indazol-6-yl)amino]-N-[4-(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 454480-89-8 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-(1,2,3,6-tetrahydro-1-methyl-4-pyridinyl)phenyl]-2-(1H-indazol-6-ylamino)- (9CI) (CA INDEX NAME)



RN 454480-90-1 CAPLUS


CN 3-Pyridinecarboxamide, 2-(1H-indazol-6-ylamino)-N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]- (9CI) (CA INDEX NAME)



RN 454480-95-6 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-[(1S)-1-aminoethyl]phenyl]-2-(1H-indazol-6-ylamino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 454480-97-8 CAPLUS


CN 3-Pyridinecarboxamide, 2-(1H-indazol-6-ylamino)-N-[4-[(1S)-1-[(1-methylethyl)amino]ethyl]phenyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 454480-96-7

CMF C24 H26 N6 O


Absolute stereochemistry.



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 454480-98-9 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-(4-methyl-1-piperazinyl)phenyl]-2-(1H-indazol-6-ylamino)- (9CI) (CA INDEX NAME)




RN 454481-00-6 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-2-(4-methyl-1-piperazinyl)phenyl]-2-(1H-indazol-6-ylamino)- (9CI) (CA INDEX NAME)




RN 454481-07-3 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[3-[2-(dimethylamino)ethoxy]-1H-indazol-6-yl]amino]-N-[4-(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 454481-12-0 CAPLUS

CN 3-Pyridinecarboxamide, N-[1,1'-biphenyl]-4-yl-2-(1H-indazol-6-ylamino)- (9CI) (CA INDEX NAME)




RN 454481-17-5 CAPLUS

CN 3-Pyridinecarboxamide, 2-(1H-indazol-6-ylamino)-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 454481-20-0 CAPLUS

CN 3-Pyridinecarboxamide, 2-(1H-indazol-6-ylamino)-N-[4-(1-methyl-4-piperidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 454481-21-1 CAPLUS


CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-[3-(1-piperidinyl)propyl]phenyl]-2-(1H-indazol-6-ylamino)- (9CI) (CA INDEX NAME)



RN 454481-22-2 CAPLUS


CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-[(1E)-4-(1-pyrrolidinyl)-1-butenyl]phenyl]-2-(1H-indazol-6-ylamino)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 454481-23-3 CAPLUS


CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-[3-(1-pyrrolidinyl)propyl]phenyl]-2-(1H-indazol-6-ylamino)- (9CI) (CA INDEX NAME)



RN 454481-24-4 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-[3-(4-morpholinyl)propyl]phenyl]-2-(1H-indazol-6-ylamino)- (9CI) (CA INDEX NAME)


NAME)




RN 454481-26-6 CAPLUS

CN 3-Pyridinecarboxamide, 2-(1H-indazol-6-ylamino)-N-[4-[3-(4-methyl-1-piperazinyl)-3-oxopropyl]phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 454481-28-8 CAPLUS


CN 3-Pyridinecarboxamide, 2-(1H-indazol-6-ylamino)-N-[4-[3-(4-methyl-1-piperazinyl)propyl]phenyl]- (9CI) (CA INDEX NAME)




RN 454481-30-2 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-[1,1-dimethyl-3-(4-morpholinyl)propyl]phenyl]-2-(1H-indazol-6-ylamino)- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A



RN 454481-31-3 CAPLUS
CN 3-Pyridinecarboxamide, 2-(1H-indazol-6-ylamino)-N-[4-[2,2,2-trifluoro-1-[2-(2-methoxyethoxy)ethoxy]ethoxy]-1-(trifluoromethyl)ethyl]phenyl]- (9CI) (CA INDEX NAME)




RN 454481-32-4 CAPLUS

CN 3-Pyridinecarboxamide, 2-(1H-indazol-6-ylamino)-N-[4-[2,2,2-trifluoro-1-[2-(2-methoxyethoxy)ethoxy]-1-(trifluoromethyl)ethyl]phenyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 454481-31-3


CMF C27 H25 F6 N5 O4



CM 2

CRN 76-05-1


CMF C2 H F3 O2




RN 454481-33-5 CAPLUS

CN 3-Pyridinecarboxamide, 2-(1H-indazol-6-ylamino)-N-[4-[2,2,2-trifluoro-1-[2-(1-piperidinyl)ethoxy]-1-(trifluoromethyl)ethyl]phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 454481-34-6 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)phenyl]-6-fluoro-2-(1H-indazol-6-ylamino)- (9CI) (CA INDEX NAME)




RN 454481-35-7 CAPLUS

CN 3-Pyridinecarboxamide, 6-fluoro-2-(1H-indazol-6-ylamino)-N-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 454481-45-9 CAPLUS

CN 3-Pyridinecarboxamide, 2-(1H-indazol-6-ylamino)-N-[3-[(1-methyl-4-piperidinyl)methoxy]-4-(pentafluoroethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 454481-46-0 CAPLUS


CN 3-Pyridinecarboxamide, 2-(1H-indazol-6-ylamino)-N-[3-[[1-(1-methylethyl)-4-piperidinyl]methoxy]-4-(pentafluoroethyl)phenyl]-(9CI) (CA INDEX NAME)



RN 454481-47-1 CAPLUS


CN 3-Pyridinecarboxamide, N-[3-[(2R)-2-hydroxy-3-(1-pyrrolidinyl)propoxy]-4-(pentafluoroethyl)phenyl]-2-(1H-indazol-6-ylamino)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 454481-48-2 CAPLUS


CN 3-Pyridinecarboxamide, 2-(1H-indazol-6-ylamino)-N-[4-(pentafluoroethyl)-3-[2-(1-piperidinyl)ethoxy]phenyl]-(9CI) (CA INDEX NAME)



RN 454481-49-3 CAPLUS

CN 3-Pyridinecarboxamide, N-[3-[(2S)-2-hydroxy-3-(1-pyrrolidinyl)propoxy]-4-(pentafluoroethyl)phenyl]-2-(1H-indazol-6-ylamino)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 454481-50-6 CAPLUS

CN 3-Pyridinecarboxamide, 2-(1H-indazol-6-ylamino)-N-[4-(pentafluoroethyl)-3-[(2S)-2-pyrrolidinylmethoxy]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 454481-51-7 CAPLUS

CN 3-Pyridinecarboxamide, 2-(1H-indazol-6-ylamino)-N-[4-(pentafluoroethyl)-3-[(2R)-2-pyrrolidinylmethoxy]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 454481-52-8 CAPLUS


CN 3-Pyridinecarboxamide, 2-(1H-indazol-6-ylamino)-N-[3-[(2R)-2-(pyrrolidinylmethoxy)-4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 454481-53-9 CAPLUS

CN 3-Pyridinecarboxamide, 2-(1H-indazol-6-ylamino)-N-[3-[2-(1-pyrrolidinyl)ethoxy]-4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 454481-55-1 CAPLUS

CN 3-Pyridinecarboxamide, 2-(1H-indazol-6-ylamino)-N-[4-[1-methyl-1-(1-methyl-4-piperidinyl)ethyl]phenyl]- (9CI) (CA INDEX NAME)



RN 454481-60-8 CAPLUS


CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-(4-piperidinylmethoxy)phenyl]-2-(1H-indazol-6-ylamino)- (9CI) (CA INDEX NAME)



RN 454481-62-0 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 2-[[[2-(1,1-dimethylethyl)-5-[[[2-(1H-indazol-6-ylamino)-3-pyridinyl]carbonyl]amino]phenoxy]methyl]-, 1,1-dimethylethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 454481-63-1 CAPLUS


CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-[(2S)-2-tert-butylpyrrolidinylmethoxy]phenyl]-2-(1H-indazol-6-ylamino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 454481-65-3 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-(1-piperazinyl)phenyl]-2-(1H-indazol-6-ylamino)- (9CI) (CA INDEX NAME)




RN 454481-69-7 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-(4-propyl-1-piperazinyl)phenyl]-2-(1H-indazol-6-ylamino)- (9CI) (CA INDEX NAME)




RN 454481-70-0 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-[4-(1-methylethyl)-1-piperazinyl]phenyl]-2-(1H-indazol-6-ylamino)- (9CI) (CA INDEX NAME)




RN 454481-75-5 CAPLUS

CN 3-Pyridinecarboxamide, 2-(1H-indazol-6-ylamino)-N-[3-[(4-methyl-1-piperazinyl)methyl]-4-(pentafluoroethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 454481-76-6 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[5-[[[2-(1H-indazol-6-ylamino)-3-pyridinyl]carbonyl]amino]-2-(pentafluoroethyl)phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 454481-77-7 CAPLUS

CN 3-Pyridinecarboxamide, 2-(1H-indazol-6-ylamino)-N-[3-(4-morpholinylmethyl)-4-(pentafluoroethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 454481-78-8 CAPLUS

CN 3-Pyridinecarboxamide, 2-(1H-indazol-6-ylamino)-N-[4-(pentafluoroethyl)-3-(1-piperazinylmethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 454481-79-9 CAPLUS


CN 1-Piperazinecarboxylic acid, 4-[2-(1,1-dimethylethyl)-5-[[[2-(1H-indazol-6-ylamino)-3-pyridinyl]carbonyl]amino]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 454481-83-5 CAPLUS


CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-[[2-(4-morpholinyl)ethyl]amino]phenyl]-2-(1H-indazol-6-ylamino)- (9CI) (CA INDEX NAME)






RN 454481-84-6 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[2-(1,1-dimethylethyl)-5-[[[2-(1H-indazol-6-ylamino)-3-pyridinyl]carbonyl]amino]phenyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 454481-89-1 CAPLUS

CN 3-Pyridinecarboxamide, 2-(1H-indazol-6-ylamino)-N-[4-(pentafluoroethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 454481-90-4 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-(4-piperidinylamino)phenyl]-2-(1H-indazol-6-ylamino)- (9CI) (CA INDEX NAME)




RN 454481-99-3 CAPLUS

CN 3-Pyridinecarboxamide, N-[3-[3-(dimethylamino)-1-propynyl]-4-(1,1-dimethylethyl)phenyl]-2-(1H-indazol-6-ylamino)- (9CI) (CA INDEX NAME)



RN 454482-04-3 CAPLUS

CN 3-Pyridinecarboxamide, 2-[(2,3-dihydro-2-oxo-1H-benzimidazol-5-yl)amino]-N-[4-(pentafluoroethyl)phenyl]- (9CI) (CA INDEX NAME)




IT 454481-81-3

RL: RCT (Reactant); RACT (Reactant or reagent)

(prepn. of substituted 2-(1H-indazol-6-ylamino)nicotinamides for treating KDR-related diseases)

RN 454481-81-3 CAPLUS

CN 3-Pyridinecarboxamide, N-[3-amino-4-(1,1-dimethylethyl)phenyl]-2-(1H-indazol-6-ylamino)- (9CI) (CA INDEX NAME)




IT 454482-08-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(prepn. of substituted 2-(1H-indazol-6-ylamino)nicotinamides for treating KDR-related diseases)

RN 454482-08-7 CAPLUS


CN 3-Pyridinecarboxamide, N-[3-[(2-bromoethyl)amino]-4-(1,1-dimethylethyl)phenyl]-2-(1H-indazol-6-ylamino)- (9CI) (CA INDEX NAME)



GI



I



II

AB The title compds. [I; each of A1 and A2 = C, CH, N; A = 5-6 membered partially satd. heterocyclyl, 5-6 membered heteroaryl, 9-11 membered fused partially satd. heterocyclyl, etc.; X = C(:Z)N(R5a)R4; Z = O, S; R = (un)substituted 4-6 membered heterocyclyl, aryl, fused 9-14 membered bicyclic or tricyclic heterocyclyl; R1 = (un)substituted 6-10 membered aryl, 4-6 membered heterocyclyl, cycloalkyl, etc.; R2 = H, halo, cycloalkyl, etc.; R4 = a bond, alkylene, alkenylene, etc.; R5 = H, alkyl, (un)substituted Ph, aralkyl; R5a is not defined] which are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases, were prepd. Thus, heating N-(4-chlorophenyl)-2-chloro-3-pyridinecarboxamide with 6-aminoindazole at 150.degree. for 2 h afforded II which inhibited VEGF-stimulated HUVEC proliferation at level below 50 nM. Compds. I showed inhibition of KDR at doses less than 50 .mu.M.

L4 ANSWER 5 OF 20 CAPLUS COPYRIGHT 2003 ACS

AN 2002:658116 CAPLUS

DN 137:201332

TI Preparation of heterocyclylalkylamine derivatives as remedies for angiogenesis mediated diseases

IN Chen, Guoqing; Adams, Jeffrey; Bemis, Jean; Booker, Shon; Cai, Guolin; Croghan, Michael; Dipietro, Lucian; Dominguez, Celia; Elbaum, Daniel;

Germain, Julie; Geuns-meyer, Stephanie; Handley, Michael; Huang, Qi; Kim, Joseph L.; Kim, Tae-seong; Kiselyov, Alexander; Ouyang, Xiaohu; Patel, Vinod F.; Smith, Leon M.; Stec, Markian; Tasker, Andrew; Xi, Ning; Xu, Shimin; Yuan, Chester Chenguang

PA Amgen Inc., USA

SO PCT Int. Appl., 502 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002066470	A1	20020829	WO 2002-US743	20020111
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2001-261339PP 20010112				
US 2001-323764PP 20010919				
US 2002-46681 A 20020110				

OS MARPAT 137:201332


IT 453561-73-4P 453561-77-8P 453561-95-0P

453562-83-9P 453563-79-6P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (prepn. of heterocyclalkylamine derivs. as remedies for angiogenesis mediated diseases)


RN 453561-73-4 CAPLUS

CN 3-Pyridinecarboxamide, 6-chloro-5-fluoro-N-[4-(1-methylethyl)phenyl]-2-[(4-pyridinylmethyl)amino] - (9CI) (CA INDEX NAME)




RN 453561-77-8 CAPLUS

CN Carbamic acid, [2-[4-[[[2-[(4-pyridinylmethyl)amino]-3-pyridinyl]carbonyl]amino]phenyl]ethyl]-, 1,1-dimethylethyl ester (9CI)
 (CA INDEX NAME)




RN 453561-95-0 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-nitrophenyl]-2-[(2-pyridinylmethyl)amino]-(9CI) (CA INDEX NAME)



RN 453562-83-9 CAPLUS


CN 3-Pyridinecarboxamide, 2-[[[2-chloro-4-pyridinyl)methyl]amino]-N-[4-(1,1-dimethylethyl)phenyl]-(9CI) (CA INDEX NAME)



RN 453563-79-6 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)phenyl]-2-[[[2-[[1-(diphenylmethyl)-3-azetidinyl]oxy]-4-pyridinyl)methyl]amino]-(9CI) (CA

INDEX NAME)



IT 352227-65-7P 352227-74-8P 453561-12-1P
453561-21-2P 453561-29-0P 453561-33-6P
453561-38-1P 453561-72-3P 453561-76-7P
453561-78-9P 453561-80-3P 453561-83-6P
453561-87-0P, (S)-N-[3-(Pyrrolidin-2-ylmethoxy)-4-pentafluoroethylphenyl]-2-[(pyridin-4-ylmethyl)amino]nicotinamide
453561-88-1P, (R)-N-[3-(Pyrrolidin-2-ylmethoxy)-4-trifluoromethylphenyl]-2-[(pyridin-4-ylmethyl)amino]nicotinamide
453561-89-2P, (R)-N-[3-(Pyrrolidin-2-ylmethoxy)-4-pentafluoroethylphenyl]-2-[(pyridin-4-ylmethyl)amino]nicotinamide
453561-93-8P, N-[4-tert-Butyl-3-[(piperidin-4-yl)methoxy]phenyl]-2-[(pyridin-4-ylmethyl)amino]nicotinamide 453561-94-9P,
N-[4-tert-Butyl-3-(pyrrolidin-2-ylmethoxy)phenyl]-2-[(pyridin-4-ylmethyl)amino]nicotinamide 453561-96-1P 453561-98-3P
453562-02-2P 453562-03-3P 453562-05-5P
453562-20-4P 453562-21-5P 453562-23-7P
453562-29-3P 453562-52-2P 453562-56-6P
453562-76-0P 453562-80-6P 453562-84-0P
453562-85-1P 453562-87-3P 453562-91-9P
453562-92-0P 453562-93-1P 453562-96-4P
453563-02-5P 453563-06-9P 453563-08-1P
453563-10-5P 453563-15-0P 453563-17-2P
453563-18-3P 453563-20-7P 453563-22-9P
453563-23-0P 453563-24-1P 453563-25-2P
453563-27-4P 453563-29-6P 453563-32-1P
453563-33-2P 453563-38-7P 453563-39-8P
453563-40-1P 453563-41-2P 453563-45-6P
453563-46-7P 453563-47-8P 453563-50-3P
453563-51-4P 453563-54-7P 453563-55-8P
453563-56-9P 453563-58-1P 453563-61-6P
453563-63-8P 453563-65-0P 453563-67-2P
453563-68-3P 453563-70-7P 453563-81-0P
453563-84-3P 453563-85-4P 453563-86-5P
453563-87-6P 453563-88-7P 453563-89-8P
453563-90-1P 453563-91-2P 453563-92-3P
453563-93-4P 453563-94-5P 453563-99-0P
453564-00-6P 453564-03-9P 453564-04-0P
453564-06-2P 453564-11-9P 453564-13-1P


453564-14-2P 453564-15-3P 453564-34-6P
 453564-36-8P 453564-42-6P 453564-45-9P
 453564-47-1P 453564-48-2P 453564-66-4P
 453564-67-5P 453564-68-6P 453564-69-7P
 453564-70-0P 453564-71-1P 453564-84-6P
 453564-85-7P 453564-86-8P 453564-92-6P
 453564-94-8P 453564-99-3P 453565-02-1P
 453565-03-2P 453565-09-8P 453565-10-1P
 453565-11-2P 453565-15-6P 453565-17-8P
 453565-25-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of heterocyclalkylamine derivs. as remedies for angiogenesis mediated diseases)


RN 352227-65-7 CAPLUS

CN 3-Pyridinecarboxamide, N-(4-butylphenyl)-2-[(4-pyridinylmethyl)amino]-(9CI) (CA INDEX NAME)




RN 352227-74-8 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)phenyl]-2-[(4-pyridinylmethyl)amino]-(9CI) (CA INDEX NAME)




RN 453561-12-1 CAPLUS

CN 3-Pyridinecarboxamide, N-(3-fluoro-4-methylphenyl)-6-methyl-2-[(4-pyridinylmethyl)amino]-(9CI) (CA INDEX NAME)




RN 453561-21-2 CAPLUS

CN 3-Pyridinecarboxamide, N-(3-fluoro-4-methylphenyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 453561-29-0 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1-methylethyl)phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 453561-33-6 CAPLUS

CN 3-Pyridinecarboxamide, 2-[(4-pyridinylmethyl)amino]-N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]- (9CI) (CA INDEX NAME)




RN 453561-38-1 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(4-hydroxybutyl)phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 453561-72-3 CAPLUS

CN 3-Pyridinecarboxamide, 5-fluoro-N-[4-(1-methylethyl)phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 453561-76-7 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(4-morpholinylmethyl)phenyl]-2-[(4-pyridinylmethyl)amino] - (9CI) (CA INDEX NAME)




RN 453561-78-9 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(2-aminoethyl)phenyl]-2-[(4-pyridinylmethyl)amino] - (9CI) (CA INDEX NAME)




RN 453561-80-3 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)phenyl]-2-[[[2-[2-(1-methyl-2-pyrrolidinyl)ethoxy]-4-pyridinyl)methyl]amino] - (9CI) (CA INDEX NAME)



RN 453561-83-6 CAPLUS


CN 3-Pyridinecarboxamide, N-[4-(pentafluoroethyl)-3-(1-piperazinylmethyl)phenyl]-2-[(4-pyridinylmethyl)amino]-(9CI) (CA INDEX NAME)




RN 453561-87-0 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(pentafluoroethyl)-3-[(2S)-2-pyrrolidinylmethoxy]phenyl]-2-[(4-pyridinylmethyl)amino]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 453561-88-1 CAPLUS

CN 3-Pyridinecarboxamide, 2-[(4-pyridinylmethyl)amino]-N-[3-[(2R)-2-pyrrolidinylmethoxy]-4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 453561-89-2 CAPLUS


CN 3-Pyridinecarboxamide, N-[4-(pentafluoroethyl)-3-[(2R)-2-pyrrolidinylmethoxy]phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 453561-93-8 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-(4-piperidinylmethoxy)phenyl]-2-[(4-pyridinylmethyl)amino] - (9CI) (CA INDEX NAME)




RN 453561-94-9 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-(2-pyrrolidinylmethoxy)phenyl]-2-[(4-pyridinylmethyl)amino] - (9CI) (CA INDEX NAME)




RN 453561-96-1 CAPLUS

CN 3-Pyridinecarboxamide, N-[3-amino-4-(1,1-dimethylethyl)phenyl]-2-[(2-pyridinylmethyl)amino] - (9CI) (CA INDEX NAME)




RN 453561-98-3 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1-methylethyl)phenyl]-2-[(2-pyridinylmethyl)amino] - (9CI) (CA INDEX NAME)




RN 453562-02-2 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(pentafluoroethyl)phenyl]-2-[(4-pyridinylmethyl)amino] - (9CI) (CA INDEX NAME)




RN 453562-03-3 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(nonafluorobutyl)phenyl]-2-[(4-pyridinylmethyl)amino] - (9CI) (CA INDEX NAME)




RN 453562-05-5 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1-methylethyl)phenyl]-2-[[2-(1H-1,2,4-triazol-1-yl)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 453562-20-4 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1-methylpropyl)phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 453562-21-5 CAPLUS

CN 3-Pyridinecarboxamide, N-(4-methylphenyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 453562-23-7 CAPLUS

CN 3-Pyridinecarboxamide, N-(4-ethylphenyl)-2-[(4-pyridinylmethyl)amino]-
(9CI) (CA INDEX NAME)


RN 453562-29-3 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(phenylmethyl)phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 453562-52-2 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-(4-methyl-1-piperazinyl)phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 453562-56-6 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(4-methyl-1-piperazinyl)phenyl]-2-[(4-pyridinylmethyl)amino] - (9CI) (CA INDEX NAME)




RN 453562-76-0 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-[1,1-dimethyl-3-(4-morpholinyl)propyl]phenyl]-2-[(4-pyridinylmethyl)amino] - (9CI) (CA INDEX NAME)




RN 453562-80-6 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)phenyl]-2-[[[2-[(1-methyl-4-piperidinyloxy)methoxy]-4-pyridinyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 453562-84-0 CAPLUS


CN 3-Pyridinecarboxamide, 2-[[[2-[3-(dimethylamino)-1-propynyl]-4-pyridinyl]methyl]amino]-N-[4-(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 453562-85-1 CAPLUS


CN 3-Pyridinecarboxamide, 2-[[[2-methoxy-4-pyridinyl)methyl]amino]-N-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)






RN 453562-87-3 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-[3-(1-piperidinyl)propyl]phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 453562-91-9 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-[3-(1-pyrrolidinyl)propyl]phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 453562-92-0 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-[(1E)-4-(1-pyrrolidinyl)]-1-pyridinylmethyl]phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)


1-butenyl]phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 453562-93-1 CAPLUS


CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-[3-(4-morpholinyl)propyl]phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 453562-96-4 CAPLUS


CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)phenyl]-2-[(4-pyrimidinylmethyl)amino]- (9CI) (CA INDEX NAME)






RN 453563-02-5 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[[2-[2-(dimethylamino)ethoxy]ethoxy]-4-pyridinyl]methyl]amino]-N-[4-(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 453563-06-9 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-[1-(2-cyclohexylethoxy)-2,2,2-trifluoro-1-(trifluoromethyl)ethyl]phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 453563-08-1 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)phenyl]-6-fluoro-2-[(4-pyridinylmethyl)amino] - (9CI) (CA INDEX NAME)




RN 453563-10-5 CAPLUS

CN 3-Pyridinecarboxamide, 6-fluoro-N-[4-(1-methylethyl)phenyl]-2-[(4-pyridinylmethyl)amino] - (9CI) (CA INDEX NAME)




RN 453563-15-0 CAPLUS

CN 3-Pyridinecarboxamide, N-[1,1'-biphenyl]-4-yl-2-[(4-pyridinylmethyl)amino] - (9CI) (CA INDEX NAME)



RN 453563-17-2 CAPLUS


CN 3-Pyridinecarboxamide, N-(4-cyclohexylphenyl)-2-[(4-pyridinylmethyl)amino]-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl

RN 453563-18-3 CAPLUS


CN 3-Pyridinecarboxamide, N-[4-(1H-imidazol-1-yl)phenyl]-2-[(4-pyridinylmethyl)amino]-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl

RN 453563-20-7 CAPLUS


CN 3-Pyridinecarboxamide, N-[4-(4-morpholinyl)phenyl]-2-[(4-pyridinylmethyl)amino]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 453563-22-9 CAPLUS


CN 3-Pyridinecarboxamide, 2-[(4-pyridinylmethyl)amino]-N-[4-(trifluoromethyl)phenyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 453563-23-0 CAPLUS


CN Benzoic acid, 4-[[[2-[(4-pyridinylmethyl)amino]-3-pyridinyl]carbonyl]amino]-, methyl ester, hydrochloride (9CI) (CA INDEX NAME)



● x HCl


RN 453563-24-1 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1-methylethyl)phenyl]-2-[(4-quinolinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 453563-25-2 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)phenyl]-2-[(6-quinolinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 453563-27-4 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[[2,3-dihydro-5-benzofuranyl)methyl]amino]-N-[4-(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 453563-29-6 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[[2-[[[1-(1-methylethyl)-3-azetidinyl]methoxy]-4-pyridinyl]methyl]amino]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 453563-32-1 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)phenyl]-2-[[[2-[[[1-(1-methylethyl)-3-azetidinyl]methoxy]-4-pyridinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 453563-33-2 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[[(2,3-dihydro-5-benzofuranyl)methyl]amino]-N-[4-[1-methyl-1-(1-methyl-4-piperidinyl)ethyl]phenyl]- (9CI) (CA INDEX NAME)




RN 453563-38-7 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[[2-[2-(1-methyl-4-piperidinyl)ethoxy]-4-pyridinyl]methyl]amino]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 453563-39-8 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[[2-[2-(1-methyl-2-pyrrolidinyl)ethoxy]-4-pyridinyl]methyl]amino]-N-[4-(pentafluoroethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 453563-40-1 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(pentafluoroethyl)phenyl]-2-[[[2-[2-(2-methyl-2-pyrrolidinyl)ethoxy]-4-pyridinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 453563-41-2 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)phenyl]-2-[[[2-[2-(2-pyrrolidinyl)ethoxy]-4-pyridinyl]methyl]amino]-(9CI) (CA INDEX NAME)




RN 453563-45-6 CAPLUS

CN 3-Pyridinecarboxamide, N-[3-[(4-methyl-1-piperazinyl)methyl]-4-(pentafluoroethyl)phenyl]-2-[(4-pyridinylmethyl)amino]-(9CI) (CA INDEX NAME)




RN 453563-46-7 CAPLUS

1-Piperazinecarboxylic acid, 4-[[2-(pentafluoroethyl)-5-[[[2-(4-pyridinylmethyl)amino]-3-pyridinyl]carbonyl]amino]phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 453563-47-8 CAPLUS

3-Pyridinylcarboxamide, 2-[[[2-[3-(1-methyl-4-piperidinyloxy]propoxy]-4-pyridinyl]methyl]amino]-N-[4-(pentafluoroethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 453563-50-3 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[[2-[3-(4-morpholinyl)propoxy]-4-pyridinyl]methyl]amino]-N-[4-(pentafluoroethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 453563-55-8 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)phenyl]-2-[[[2-[2-(4-morpholinyl)ethoxy]-4-pyridinyl]methyl]amino]-(9CI) (CA INDEX NAME)




RN 453563-56-9 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[[2-[2-(4-morpholinyl)ethoxy]-4-pyridinyl]methyl]amino]-N-[4-(trifluoromethyl)phenyl]-(9CI) (CA INDEX NAME)



RN 453563-58-1 CAPLUS


CN 3-Pyridinecarboxamide, 2-[[[2-[2-(4-morpholinyl)ethoxy]-4-pyridinyl]methyl]amino]-N-[4-(pentafluoroethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 453563-61-6 CAPLUS


CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)phenyl]-2-[[[2-[[[2R]-1-methyl-2-pyrrolidinyl]methoxy]-4-pyridinyl]methyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 453563-63-8 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 2-[[2-(1,1-dimethylethyl)-5-[[[2-[(4-pyridinylmethyl)amino]-3-pyridinyl]carbonyl]amino]phenoxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 453563-65-0 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[[2-[(1-methyl-4-piperidiny)methoxy]-4-pyridinyl)methyl]amino]-N-[4-(pentafluoroethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 453563-67-2 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)phenyl]-2-[[[2-[[3-(4-morpholinyl)propyl]amino]-4-pyrimidinyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 453563-68-3 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[[2-[[3-(4-morpholinyl)propyl]amino]-4-pyrimidinyl]methyl]amino]-N-[4-(pentafluoroethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 453563-70-7 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)phenyl]-2-[[[2-[[2-(1-methyl-2-pyrrolidinyl)ethyl]amino]-4-pyrimidinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 453563-81-0 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)phenyl]-2-[[[2-[[2-(1-methyl-4-piperidinyl)ethoxy]-4-pyridinyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 453563-84-3 CAPLUS


CN 1-Pyrrolidinecarboxylic acid, 2-[[5-[[[2-[[[(2,3-dihydro-6-benzofuranyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-2-(pentafluoroethyl)phenoxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 453563-85-4 CAPLUS

CN 3-Pyridinecarboxamide, N-[3-[(2R)-2-hydroxy-3-(1-pyrrolidinyl)propoxy]-4-(pentafluoroethyl)phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 453563-86-5 CAPLUS


CN 3-Pyridinecarboxamide, N-[3-[(2S)-2-hydroxy-3-(1-pyrrolidinyl)propoxy]-4-(pentafluoroethyl)phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 453563-87-6 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-[(1-methyl-4-piperidinyl)methoxy]phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 453563-88-7 CAPLUS

CN 3-Pyridinecarboxamide, N-[3-[(1-methyl-4-piperidinyl)methoxy]-4-(pentafluoroethyl)phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 453563-89-8 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(pentafluoroethyl)-3-[2-(1-piperidinyl)ethoxy]phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 453563-90-1 CAPLUS


CN 3-Pyridinecarboxamide, N-[3-[2-(1-piperidinyl)ethoxy]-4-(trifluoromethyl)phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 453563-91-2 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 2-[[2-(pentafluoroethyl)-5-[[[2-[(4-pyridinylmethyl)amino]-3-pyridinyl]carbonyl]amino]phenoxy]methyl]-, 1,1-dimethylethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 453563-92-3 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 2-[[5-[[[2-[(4-pyridinylmethyl)amino]-3-pyridinyl]carbonyl]amino]-2-(trifluoromethyl)phenoxy]methyl]-, 1,1-dimethylethyl ester, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 453563-93-4 CAPLUS


CN 1-Pyrrolidinecarboxylic acid, 2-[[2-(pentafluoroethyl)-5-[[[2-[(4-pyridinylmethyl)amino]-3-pyridinyl]carbonyl]amino]phenoxy]methyl]-, 1,1-dimethylethyl ester, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 453563-94-5 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)phenyl]-2-[[[2-[(1-methyl-4-piperidinyl)oxy]-4-pyridinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 453563-99-0 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[2-(1,1-dimethylethyl)-5-[[[2-[(4-pyridinylmethyl)amino]-3-pyridinyl]carbonyl]amino]phenoxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 453564-00-6 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-[(1-methyl-3-azetidinyloxy)methoxy]phenyl]-2-[(4-pyridinylmethyl)amino]-(9CI) (CA INDEX NAME)




RN 453564-03-9 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-[1-methyl-1-(1-methyl-4-piperidinylethyl)phenyl]-2-[(4-pyridinylmethyl)amino]-(9CI) (CA INDEX NAME)




RN 453564-04-0 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[[2-methoxy-4-pyridinyl)methyl]amino]-N-[4-[1-methyl-1-(1-methyl-4-piperidiny]ethyl]phenyl]- (9CI) (CA INDEX NAME)




RN 453564-06-2 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[[2-[3-(dimethylamino)propoxy]-4-pyridinyl)methyl]amino]-N-[4-(pentafluoroethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 453564-11-9 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[[4-pyridinyl)methyl]amino]-N-[3-[2-(1-pyrrolidinyl)ethoxy]-4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 453564-13-1 CAPLUS

CN 1-Azetidinecarboxylic acid, 3-[[2-(1,1-dimethylethyl)-5-[[[2-[(4-pyridinylmethyl)amino]-3-pyridinyl]carbonyl]amino]phenoxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 453564-14-2 CAPLUS

CN Benzeneacetic acid, .alpha.,.alpha.-dimethyl-4-[[[2-[(4-pyridinylmethyl)amino]-3-pyridinyl]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 453564-15-3 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[[2-[[3-(4-morpholinyl)propyl]amino]-4-pyrimidinyl]methyl]amino]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 453564-34-6 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(pentafluoroethyl)phenyl]-2-[(4-pyrimidinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 453564-36-8 CAPLUS


CN 3-Pyridinecarboxamide, 2-[[[2-(3-azetidinyloxy)-4-pyridinyl]methyl]amino]-N-[4-(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 453564-42-6 CAPLUS


CN 3-Pyridinecarboxamide, 2-[[[(2,3-dihydro-5-benzofuranyl)methyl]amino]-N-[4-(pentafluoroethyl)-3-[(2S)-2-pyrrolidinylmethoxy]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 453564-45-9 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(pentafluoroethyl)phenyl]-2-[[[(tetrahydro-2H-pyran-4-yl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 453564-47-1 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1-methylethyl)phenyl]-2-[[[2-(3-pyridinyl)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 453564-48-2 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)phenyl]-2-[[2-(3-pyridinyl)ethyl]amino]-(9CI) (CA INDEX NAME)




RN 453564-66-4 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[4-(pyridinylmethyl)amino]-N-[4-[2,2,2-trifluoro-1-[2-(1-piperidinyl)ethoxy]-1-(trifluoromethyl)ethyl]phenyl]-(9CI) (CA INDEX NAME)



RN 453564-67-5 CAPLUS


CN 3-Pyridinecarboxamide, N-[1,1'-biphenyl]-4-yl-2-[(4-pyridinylmethyl)amino]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 453564-68-6 CAPLUS


CN 3-Pyridinecarboxamide, N-(4-cyclohexylphenyl)-2-[(4-pyridinylmethyl)amino]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 453564-69-7 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)phenyl]-2-[(7-quinolinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 453564-70-0 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)phenyl]-2-[[2-ethyl-4-pyridinyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 453564-71-1 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[[2-[(1-methyl-4-piperidinyl)methoxy]-4-pyridinyl)methyl]amino]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 453564-84-6 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[[2-[(1-methyl-4-piperidinyloxy]-4-pyridinyl)methyl]amino]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 453564-85-7 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[[2-[(1-methyl-4-piperidinyloxy]-4-pyridinyl)methyl]amino]-N-[4-(pentafluoroethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 453564-86-8 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)phenyl]-2-[[[2-[(1-methyl-2-pyrrolidinyl)methoxy]-4-pyridinyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 453564-92-6 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[[2-[3-(1-methyl-4-piperidinyloxy)propoxy]-4-pyridinyl]methyl]amino]-N-[4-(tert-butyl)phenyl]- (9CI) (CA INDEX NAME)




RN 453564-94-8 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)phenyl]-2-[[[2-[3-(1-methyl-4-piperidinyloxy)propoxy]-4-pyridinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 453564-99-3 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[2-(1,1-dimethylethyl)-5-[[[2-[(4-pyridinylmethyl)amino]-3-pyridinyl]carbonyl]amino]phenyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 453565-02-1 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1-methylpropyl)phenyl]-2-[[2-(3-pyridinyl)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 453565-03-2 CAPLUS


CN 3-Pyridinecarboxamide, N-[4-(pentafluoroethyl)phenyl]-2-[[2-(3-pyridinyl)ethyl]amino]-(9CI) (CA INDEX NAME)



RN 453565-09-8 CAPLUS


CN 3-Pyridinecarboxamide, N-[4-(pentafluoroethyl)-3-[2-(1-piperidinyl)ethoxy]phenyl]-2-[[2-(3-pyridinyl)ethyl]amino]-(9CI) (CA INDEX NAME)






RN 453565-10-1 CAPLUS

CN 3-Pyridinecarboxamide, N-[3-[2-hydroxy-3-(1-pyrrolidinyl)propoxy]-4-(pentafluoroethyl)phenyl]-2-[[2-(3-pyridinyl)ethyl]amino]-(9CI) (CA INDEX NAME)




RN 453565-11-2 CAPLUS

CN 3-Pyridinecarboxamide, N-[3-[(1-methyl-4-piperidinyl)methoxy]-4-(pentafluoroethyl)phenyl]-2-[[2-(3-pyridinyl)ethyl]amino]-(9CI) (CA INDEX NAME)




RN 453565-15-6 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[2-(4-morpholinyl)-2-(3-pyridinyl)ethyl]amino]-N-[4-(pentafluoroethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 453565-17-8 CAPLUS

CN 3-Pyridinecarboxamide, N-[3-[(4-methyl-1-piperazinyl)methyl]-4-(pentafluoroethyl)phenyl]-2-[[2-(3-pyridinyl)ethyl]amino]- (9CI) (CA INDEX NAME)



RN 453565-25-8 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-[1-methyl-1-(1-methyl-4-piperidinyl)ethyl]phenyl]-2-[[2-(3-pyridinyl)ethyl]amino]- (9CI) (CA INDEX NAME)




IT 453561-74-5

RL: RCT (Reactant); RACT (Reactant or reagent)

(prepn. of heterocyclalkylamine derivs. as remedies for angiogenesis mediated diseases)

RN 453561-74-5 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-(1,2,3,6-tetrahydro-1-methyl-4-pyridinyl)phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




IT 453561-30-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of heterocyclalkylamine derivs. as remedies for angiogenesis mediated diseases)



RN 453561-30-3 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1-methylethyl)phenyl]-2-[(4-pyridinylmethyl)amino]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

GI



AB Title compds. [I; A1, A2 independently = C, N; A = 5-, or 6-membered partially satd. heterocyclyl, 5-, or 6-membered heterocyclyl, 9-, or 10-membered fused partially satd. heterocyclyl, 9-, 10-, or 11-membered fused heteroaryl, naphthyl, 4-, 5-, or 6-membered cycloalkenyl; X = C:ZNR3, C:ZN(R3)R4; Z = O, S; Y = N:CH, NR5(CR6R7), R8N(R5)(CR6R7), NR5(CR6R7)R8; R = 5-, or 6-membered (un)substituted heterocyclyl, 9-, 10-, 11-membered heterocyclyl; R1 = 6-10-membered (un)substituted aryl, 5-, or 6-membered (un)substituted heterocyclyl, 9-11 membered (un)substituted fused heterocyclyl, cycloalkyl, cycloalkenyl; R2 = H, halo, oxo, SH, COOH, CHO; R3 = H, alkyl, 5-, or 6-membered heterocyclyl; R4 = alkylenyl, alkenylenyl, alkynylenyl; R5 = H, alkyl, aralkyl, C6H5; R6, R7 independently = H, halo, CN, alkyl; R6R7 = cycloalkyl; R8 = alkylenyl; etc.] are prepd. and are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compds., analogs, prodrugs and pharmaceutically acceptable derivs. thereof, pharmaceutical compns. and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compds. as well as to intermediates useful in such processes. Thus, the title compd. II was prepd. from Me 3-amino-2-thiophenecarboxylate, 4-chloroaniline, and 4-pyridine carboxaldehyde via coupling reaction.

RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 20 CAPLUS COPYRIGHT 2003 ACS
AN 2002:628768 CAPLUS
DN 138:130777
TI Synthesis and study of antimicrobial and antiinflammatory activity of 2-substituted nicotinic acid amines
AU Pavlova, M. V.; Mikhalev, A. I.; Kon'shin, M. E.; Vasil'eva, M. Yu.; Mardanova, L. G.; Odegova, T. F.; Vakhnin, M. I.
CS State Pharmaceutical Academy, Perm, Russia
SO Pharmaceutical Chemistry Journal (Translation of Khimiko-Farmatsevticheskii Zhurnal) (2001), 35(12), 664-666
CODEN: PCJOAU; ISSN: 0091-150X
PB Kluwer Academic/Consultants Bureau

DT Journal

LA English


IT 491832-89-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(synthesis and antimicrobial and antiinflammatory activity of 2-substituted nicotinic acid amines)

RN 491832-89-4 CAPLUS

CN 3-Pyridinecarboxamide, N-(4-acetylphenyl)-2-[[4-[[[(4,6-dimethyl-2-pyrimidinyl)amino]sulfonyl]phenyl]amino]- (9CI) (CA INDEX NAME)



AB The compds. 2-(4-sulfamylanilino)nicotinic acid amides were synthesized by heating 2-chloronicotinic acid amides with p-aminosulfanylamides in 50% acetic acid. The desired 2-aryloxynicotinic acid amides were prepd. via interaction of 2-chloronicotinic acid amides with phenols in DMF in the presence of anhyd. potassium carbonate. The antimicrobial and antiinflammatory activity of these synthesized compds. were evaluated. The antiinflammatory effect of these compds. was only slightly lower compared to that of ortophen, and some of the compds. also displayed a weak antimicrobial effect.

RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 20 CAPLUS COPYRIGHT 2003 ACS

AN 2002:539663 CAPLUS

DN 137:109210

TI Preparation of substituted arylamine derivatives and methods of use as antitumor agents

IN Chen, Guoqing; Booker, Shon; Cai, Guolin; Croghan, Michael; Dipietro, Lucian; Dominguez, Celia; Elbaum, Daniel; Germain, Julie; Huang, Qi; Kim, Joseph L.; Kim, Tae-Seong; Patel, Vinod F.; Smith, Leon M.; Tasker, Andrew; Xi, Ning; Xu, Shimin; Yuan, Chester Chenguang

PA Amgen Inc., USA

SO PCT Int. Appl., 253 pp.


CODEN: PIXXD2

DT Patent

LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002055501	A2	20020718	WO 2002-US742	20020111
	WO 2002055501	A3	20021219		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
				US 2001-261360PP	20010112
				US 2001-323686PP	20010919
				US 2002-46526 A	20020110
	US 2002147198	A1	20021010	US 2002-46526	20020110
				US 2001-261360PP	20010112
				US 2001-323686PP	20010919
OS	MARPAT 137:109210				
IT	442845-74-1P 442846-13-1P				
	RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)				
	(target compd.; prepn. of substituted aminopyridines as antitumor agents)				
RN	442845-74-1 CAPLUS				
CN	3-Pyridinecarboxamide, 6-chloro-N-(3-fluoro-4-methylphenyl)-2-[[[4-methoxyphenyl)methyl]amino]- (9CI) (CA INDEX NAME)				



RN 442846-13-1 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 2-[[[5-[[[2-[[[4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-2-(pentafluoroethyl)phenoxy]methyl]-, 1,1-dimethylethyl ester, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 442845-75-2P 442845-86-5P 442845-87-6P
 442845-88-7P 442845-89-8P 442845-90-1P
 442846-04-0P 442846-06-2P 442846-07-3P
 442846-09-5P 442846-12-0P 442846-14-2P
 442846-21-1P 442846-24-4P 442846-26-6P
 442846-27-7P 442846-35-7P 442846-37-9P
 442846-40-4P 442846-42-6P 442846-44-8P
 442846-46-0P 442846-48-2P 442846-52-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(target compd.; prepn. of substituted aminopyridines as antitumor agents)

RN 442845-75-2 CAPLUS

CN 3-Pyridinecarboxamide, 6-chloro-N-(3-fluoro-4-methylphenyl)-2-[[4-methoxyphenyl)methyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 442845-86-5 CAPLUS


CN 3-Pyridinecarboxamide, 2-[[4-(2-fluorophenyl)methyl]amino]-N-[4-(2-

methylpropyl)phenyl]- (9CI) (CA INDEX NAME)




RN 442845-87-6 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)phenyl]-2-[[[4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 442845-88-7 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[[3-methoxyphenyl)methyl]amino]-N-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 442845-89-8 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[[(3-aminophenyl)methyl]amino]-N-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 442845-90-1 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[[(4-fluorophenyl)methyl]amino]-N-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 442846-04-0 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[[(4-fluorophenyl)methyl]amino]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 442846-06-2 CAPLUS


CN 3-Pyridinecarboxamide, 2-[[[3-[3-(dimethylamino)propyl]-4-fluorophenyl]methyl]amino]-N-[4-(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442846-07-3 CAPLUS


CN 3-Pyridinecarboxamide, 2-[[[3-[3-(dimethylamino)propyl]-4-fluorophenyl]methyl]amino]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)






RN 442846-09-5 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-(1,2,3,6-tetrahydro-1-methyl-4-pyridinyl)phenyl]-2-[[4-(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 442846-12-0 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[4-(4-fluorophenyl)methyl]amino]-N-[3-[2-(1-pyrrolidinyl)ethoxy]-4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 442846-14-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[2-(1,1-dimethylethyl)-5-[[[2-[[4-(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]phenoxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 442846-21-1 CAPLUS


CN 1-Pyrrolidinecarboxylic acid, 2-[[2-(1,1-dimethylethyl)-5-[[[2-[[4-(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]phenoxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 442846-24-4 CAPLUS


CN 3-Pyridinecarboxamide, 2-[[[(4-fluorophenyl)methyl]amino]-N-[4-(pentafluoroethyl)-3-[(2R)-2-pyrrolidinylmethoxy]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 442846-26-6 CAPLUS


CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-(4-piperidinylmethoxy)phenyl]-2-[[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 442846-27-7 CAPLUS


CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-[(2R)-2-pyrrolidinylmethoxy]phenyl]-2-[[4-(4-fluorophenyl)methyl]amino]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 442846-35-7 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[4-(4-fluorophenyl)methyl]amino]-N-[4-[1-methyl-1-(1-methyl-4-piperidinyl)ethyl]phenyl]-(9CI) (CA INDEX NAME)




RN 442846-37-9 CAPLUS

CN 1,3-Benzodioxole-5-propanoic acid, .beta.-[[3-[[[4-(pentafluoroethyl)phenyl]amino]carbonyl]-2-pyridinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 442846-40-4 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[[(3,4-difluorophenyl)methyl]amino]-N-[4-(1,1-dimethylethyl)-3-[[2-(1-piperidiny)ethyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 442846-42-6 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-[[2-(1-piperidinyl)ethyl]amino]phenyl]-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 442846-44-8 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-[[2-(1-piperidinyl)ethyl]amino]phenyl]-2-[[4-(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 442846-46-0 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 2-[[5-[[[2-[[4-(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-2-(pentafluoroethyl)phenoxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 442846-48-2 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[[4-(2-(2-pyrrolidinylmethoxy)phenyl)methyl]amino]-N-[4-(4-fluorophenyl)methyl]amino]-N-(4-(pentafluoroethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442846-52-8 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-(2-pyrrolidinylmethoxy)phenyl]-2-[[[4-(4-fluorophenyl)methyl]amino]-N-(4-(pentafluoroethyl)phenyl]- (9CI) (CA INDEX NAME)



GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [B1 and B2 independently equal C or N, wherein B1B2 form part of 5-6 membered heteroaryl ring A; R1 = one or more substituents selected from H, halo, oxo, (un)substituted cycloalkyl, phenylalkyl, etc.; R2 = (un)substituted cycloalkyl, cycloalkenyl, 6-10 membered aryl or 5-6 membered heterocyclyl, etc.; R3 = (un)substituted aryl; R4 = H, alkyl, (un)substituted Ph or aralkyl; X1 = bond, alkylene, alkenylene and alkynylene, where one of the CH2 groups may be substituted with O or NH, wherein X1 is optionally substituted with OH; X2 = (un)substituted N contg. linker, e.g., -NHCH2-], and there pharmaceutically acceptable derivs., are prepd. and disclosed as agents effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. Thus, II was prepd. via arylation of 1-dimethylamino-2-propyne with 3-bromo-5-trifluoromethylaniline, hydrogenation, amidation with 2-chloropyridine-3-carbonyl chloride and chloro-substitution with 4-phenoxyaniline. Selected compds. of the invention, e.g., II, inhibited VEGF-stimulated cell proliferation at a level below 50 nM. The invention encompasses novel compds., analogs, prodrugs and pharmaceutically acceptable derivs. thereof, pharmaceutical compns. and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like.

L4 ANSWER 8 OF 20 CAPLUS COPYRIGHT 2003 ACS

AN 2001:587254 CAPLUS

DN 135:166826

TI Preparation of pyrazoles as calcium channel inhibitors

IN Kubota, Koichi; Yonetoku, Yasuhiro; Okamoto, Yoshinori; Ishikawa, Atsushi; Takeuchi, Makoto

PA Yamanouchi Pharmaceutical Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 19 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

PATENT NO.

KIND

DATE


APPLICATION NO.

DATE

Patel


<6/30/2003>

PI JP 2001220390 A2 20010814 JP 2000-31493 20000209
 JP 2000-31493 20000209
 OS MARPAT 135:166826
 IT **353457-98-4P**
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of pyrazoles as calcium channel inhibitors)
 RN 353457-98-4 CAPLUS
 CN 3-Pyridinecarboxamide, 6-[(2-methylpropyl)amino]-N-[4-[4,5,6,7-tetrahydro-3-(trifluoromethyl)-1H-indazol-1-yl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

GI




AB Title compds. I [one of Ra and Rb = H, lower alkyl, alkenyl, alkynyl, cycloalkyl, etc.; Rb and the other substitute of Ra and Rc form (un)substituted C3-6 alkylene, alkenylene; B = (un)substituted phenylene; A = (un)substituted aryl; monocyclic or dicyclic heteroaryl] or their pharmaceutically acceptable salts are prepd. 4-(3-Trifluoromethyl-4,5,6,7-tetrahydro-1H-indazol-1-yl)aniline (563 mg) was reacted with 356 mg nicotinoyl chloride hydrochloride in the presence of Et₃N in THF at room temp. for 13 h to give 438 mg 4'-(3-trifluoromethyl-4,5,6,7-tetrahydro-1H-indazol-1-yl)nicotinamide hydrochloride.

L4 ANSWER 9 OF 20 CAPLUS COPYRIGHT 2003 ACS
 AN 2001:565010 CAPLUS
 DN 135:137407
 TI Preparation of 2-aminonicotinamides as VEGF-receptor tyrosine kinase inhibitors
 IN Manley, Paul William; Bold, Guido
 PA Novartis A.-G., Switz.; Novartis-Erfindungen Verwaltungsgesellschaft m.b.H.
 SO PCT Int. Appl., 66 pp.
 CODEN: PIXXD2


DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001055114	A1	20010802	WO 2001-EP835	20010125
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	BR 2001007805	A	20021022	GB 2000-1930 A 20000127 BR 2001-7805 20010125 GB 2000-1930 A 20000127 WO 2001-EP835 W 20010125	
	EP 1259487	A1	20021127	EP 2001-946854 20010125	
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	NO 2002003218	A	20020916	GB 2000-1930 A 20000127 WO 2001-EP835 W 20010125 NO 2002-3218 20020702 GB 2000-1930 A 20000127 WO 2001-EP835 W 20010125	
	US 2003032656	A1	20030213	US 2002-181005 20020711 GB 2000-1930 A 20000127 WO 2001-EP835 W 20010125	
OS	MARPAT 135:137407				
IT	352227-88-4P 352227-89-5P 352227-97-5P				
	RL:	BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)			
		(prepn. of 2-aminonicotinamides as VEGF-receptor tyrosine kinase inhibitors)			
RN	352227-88-4	CAPLUS			
CN	3-Pyridinecarboxamide, 2-[[[(6-methoxy-3-pyridinyl)methyl]amino]-N-[4-(1-propynyl)-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)				




RN 352227-89-5 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1-propynyl)-3-(trifluoromethyl)phenyl]-2-[(4-pyridinylmethyl)amino] - (9CI) (CA INDEX NAME)



RN 352227-97-5 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[[(6-methoxy-3-pyridinyl)methyl]amino]-N-[4-propyl-3-(trifluoromethyl)phenyl] - (9CI) (CA INDEX NAME)




IT 352227-61-3P 352227-64-6P 352227-65-7P
 352227-69-1P 352227-70-4P 352227-74-8P
 352227-90-8P 352227-96-4P 352227-98-6P
 352228-07-0P 352228-08-1P 352228-09-2P
 352228-10-5P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of 2-aminonicotinamides as VEGF-receptor tyrosine kinase inhibitors)

RN 352227-61-3 CAPLUS


CN 3-Pyridinecarboxamide, N-[3,4-bis(trifluoromethyl)phenyl]-2-[(4-pyridinylmethyl)amino] - (9CI) (CA INDEX NAME)



RN 352227-64-6 CAPLUS


CN 3-Pyridinecarboxamide, N-(4-propylphenyl)-2-[(4-pyridinylmethyl)amino]-
(9CI) (CA INDEX NAME)

RN 352227-65-7 CAPLUS

CN 3-Pyridinecarboxamide, N-(4-butylphenyl)-2-[(4-pyridinylmethyl)amino]-
(9CI) (CA INDEX NAME)


RN 352227-69-1 CAPLUS

CN 3-Pyridinecarboxamide, N-(4-pentylphenyl)-2-[(4-pyridinylmethyl)amino]-
(9CI) (CA INDEX NAME)




RN 352227-70-4 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1-propynyl)phenyl]-2-[(4-pyridinylmethyl)amino] - (9CI) (CA INDEX NAME)




RN 352227-74-8 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)phenyl]-2-[(4-pyridinylmethyl)amino] - (9CI) (CA INDEX NAME)




RN 352227-90-8 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[[(1,6-dihydro-6-oxo-3-pyridinyl)methyl]amino]-N-[4-(1-propynyl)-3-(trifluoromethyl)phenyl]] - (9CI) (CA INDEX NAME)




RN 352227-96-4 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[[(1,6-dihydro-6-oxo-3-pyridinyl)methyl]amino]-N-[4-propyl-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 352227-98-6 CAPLUS


CN 3-Pyridinecarboxamide, N-[4-propyl-3-(trifluoromethyl)phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 352228-07-0 CAPLUS


CN 3-Pyridinecarboxamide, 2-[[[(1-oxido-4-pyridinyl)methyl]amino]-N-[4-propyl-

3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 352228-08-1 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[[(1,6-dihydro-6-oxo-3-pyridinyl)methyl]amino]-N-[4-ethyl-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 352228-09-2 CAPLUS

CN 3-Pyridinecarboxamide, N-[3,4-bis(trifluoromethyl)phenyl]-2-[[[(1,6-dihydro-6-oxo-3-pyridinyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 352228-10-5 CAPLUS

CN 3-Pyridinecarboxamide, N-[3,4-bis(trifluoromethyl)phenyl]-2-[[[(1,6-dihydro-1-methyl-6-oxo-3-pyridinyl)methyl]amino]-(9CI) (CA INDEX NAME)



GI



AB The title compds. [I; n = 1-6; W = O, S; R₁, R₃ = H, alkyl, acyl; R₂ = (un)substituted cycloalkyl, aryl, mono- or bicyclic heteroaryl comprising one or more ring N atoms and 0-2 heteroatoms selected from O and S; R, R'

= H, alkyl; X = (un)substituted aryl, mono- or bicyclic heteroaryl comprising one or more ring N atoms and 0-2 heteroatoms selected from O and S] and their pharmaceutically acceptable salts, useful for therapy of a disease which responds to an inhibition of the VEGF-receptor tyrosine kinase activity (such as neoplastic disease), were prepd. and formulated. Thus, amidation of 3-aminobenzotrifluoride with 2-chloronicotinoyl chloride followed by reacting 4-pyridineethanamine with the resulting carboxamide afforded I [n = 2; R, R' = H; X = 4-pyridyl; W = O; R1, R3 = H; R2 = 3-(F3C)C6H4].

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 20 CAPLUS COPYRIGHT 2003 ACS

AN 2000:227634 CAPLUS

DN 132:265091

TI Preparation of N-(benzamidophenyl)pyridinecarboxamides and analogs as cytokine production inhibitors

IN Brown, Dearg Sutherland; Brown, George Robert

PA Zeneca Limited, UK

SO PCT Int. Appl., 138 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000018738	A1	20000406	WO 1999-GB3144	19990921
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
			GB 1998-20770	A 19980925
			GB 1998-26938	A 19981209
			GB 1999-5969	A 19990317
CA 2340454	AA	20000406	CA 1999-2340454	19990921
			GB 1998-20770	A 19980925
			GB 1998-26938	A 19981209
			GB 1999-5969	A 19990317
AU 9961034	A1	20000417	WO 1999-GB3144	W 19990921
			AU 1999-61034	19990921
			GB 1998-20770	A 19980925
			GB 1998-26938	A 19981209
			GB 1999-5969	A 19990317
BR 9913947	A	20010612	WO 1999-GB3144	W 19990921
			BR 1999-13947	19990921
			GB 1998-20770	A 19980925
			GB 1998-26938	A 19981209
			GB 1999-5969	A 19990317
EP 1115707	A1	20010718	WO 1999-GB3144	W 19990921
			EP 1999-947653	19990921
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
			GB 1998-20770	A 19980925

JP 2002525358 T2 20020813

NO 2001001492 A 20010523

US 6455520 B1 20020924

GB 1998-26938 A 19981209
 GB 1999-5969 A 19990317
 WO 1999-GB3144 W 19990921
 JP 2000-572198 19990921
 GB 1998-20770 A 19980925
 GB 1998-26938 A 19981209
 GB 1999-5969 A 19990317
 WO 1999-GB3144 W 19990921
 NO 2001-1492 20010323
 GB 1998-20770 A 19980925
 GB 1998-26938 A 19981209
 GB 1999-5969 A 19990317
 WO 1999-GB3144 W 19990921
 US 2001-787882 20010323
 GB 1998-20770 A 19980925
 GB 1998-26938 A 19981209
 GB 1999-5969 A 19990317
 WO 1999-GB3144 W 19990921

OS MARPAT 132:265091


IT 263269-52-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(prepn. of N-(benzamido-phenyl)pyridinecarboxamides and analogs as cytokine prodn. inhibitors)

RN 263269-52-9 CAPLUS

CN 4-Pyridinecarboxamide, 2-(cyclobutylamino)-N-[4-methyl-3-[[3-[(4-methyl-1-piperazinyl)methyl]benzoyl]amino]phenyl]- (9CI) (CA INDEX NAME)



GI



II

AB R4Z4ZCONHZ1NHCOZ2R2 [I; R2 = Z3R3; R3 = (un)substituted heteroaryl; R4 = (di) (alkyl)amino(alkyl), heterocyclyl(alkyl), heteroaryl(alkyl), etc.; Z = (un)substituted phenylene; Z1= 2-halo- or -alkyl-1,5-phenylene; Z2 = bond or (CH2)1-4; Z3 = bond, O, NH, alkyleneoxy, alkyleneamino, etc.; Z4 = bond, alkylene(oxy), alkyleneamino,, etc.] were prepd. as p38 kinase inhibitors. Thus, 3-(ClCH2)C6H4COC1 was amidated by 2-methyl-5-


nitroaniline and the product aminated by 1-methylpiperazine to give, after redn. and pyridine-3-carbonyl chloride amidation, title compd. II. Data for biol. activity of I were given.

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 20 CAPLUS COPYRIGHT 2003 ACS
AN 1999:784082 CAPLUS
DN 132:22963
TI Preparation of N-(pyrazolylphenyl)alkanamides and analogs as IL-2 production inhibitors
IN Betageri, Rajashekhar; Cywin, Charles L.; Hargrave, Karl; Hoermmann, Mary Ann; Kirrane, Thomas M.; Parks, Thomas M.; Patel, Usha R.; Proudfoot, John R.; Sharma, Rajiv; Sun, Sanxing; Wang, Xiao-Jun
PA Boehringer Ingelheim Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 130 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9962885	A1	19991209	WO 1999-US12295	19990603
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
CA 2332957	AA	19991209	US 1998-88154P P	19980605
			CA 1999-2332957	19990603
			US 1998-88154P P	19980605
AU 9942299	A1	19991220	WO 1999-US12295W	19990603
			AU 1999-42299	19990603
			US 1998-88154P P	19980605
JP 2002516909	T2	20020611	WO 1999-US12295W	19990603
			JP 2000-552097	19990603
			US 1998-88154P P	19980605
US 6506747	B1	20030114	WO 1999-US12295W	19990603
			US 1999-324933	19990603
			US 1998-88154P P	19980605

OS MARPAT 132:22963
IT 251656-67-4P 251656-70-9P 251656-71-0P
251656-99-2P 251657-01-9P 251657-03-1P
251657-04-2P 251657-05-3P 251657-34-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 1-(4-aminophenyl)pyrazoles and their use as anti-inflammatory agents)
RN 251656-67-4 CAPLUS
CN 3-Pyridinecarboxamide, 2-[(4-pyridinylmethyl)amino]-N-[4-[3-(3-pyridinyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 251656-70-9 CAPLUS

CN 3-Pyridinecarboxamide, 2-[(5-hydroxypentyl)amino]-N-[4-[3-(3-pyridinyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 251656-71-0 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[2-(4-morpholinyl)ethyl]amino]-N-[4-[3-(3-pyridinyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 251656-99-2 CAPLUS

CN 4-Pyridinecarboxamide, 2-[(2-hydroxyethyl)amino]-N-[4-[3-(3-pyridinyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 251657-01-9 CAPLUS

CN 4-Pyridinecarboxamide, 2-[(5-hydroxypentyl)amino]-N-[4-[3-(3-pyridinyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 251657-03-1 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-[5-ethyl-3-(3-pyridinyl)-1H-pyrazol-1-yl]phenyl]-6-[(2-hydroxyethyl)amino]- (9CI) (CA INDEX NAME)




RN 251657-04-2 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-[5-ethyl-3-(3-pyridinyl)-1H-pyrazol-1-yl]phenyl]-6-[(5-hydroxypentyl)amino]- (9CI) (CA INDEX NAME)




RN 251657-05-3 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-[5-ethyl-3-(3-pyridinyl)-1H-pyrazol-1-yl]phenyl]-6-[[2-(4-morpholinyl)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 251657-34-8 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-[5-ethyl-3-(3-pyridinyl)-1H-pyrazol-1-yl]phenyl]-6-[(3-hydroxypropyl)amino]- (9CI) (CA INDEX NAME)



GI



AB Title compds. [I; R = R₄Z₁Z; R₁, R₃ = halo, CF₃, alkyl, alkoxy, etc.; R₂ = H, halo, Me; R₄ = (cyclo)alkyl, alkoxy, alkylamino, etc.; Z = 1,4-phenylene; Z₁ = CONH, CO₂NH, NH, etc.] were prepd. Thus, I [R = 4-(R₅HN)C₆H₄, R₁ = R₃ = CF₃, R₂ = H] (II; R₅ = H) was amidated by cyclohexanecarboxylic acid to give II (R₅ = cyclohexylcarbonyl). Data for biol. activity of I were given.

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 12 OF 20 CAPLUS COPYRIGHT 2003 ACS

AN 1998:324820 CAPLUS

DN 129:16148

TI Preparation of tricyclic benzodiazepines as vasopressin antagonists

IN Albright, Jay Donald; Venkatesan, Aranapakam M.; Dusza, John P.; Sum, Fuk-wah

PA American Cyanamid Co., USA

SO U.S., 119 pp., Cont.-in-part of U.S. 5,536,718.

CODEN: USXXAM

DT Patent

Patel

<6/30/2003>

LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5753648	A	19980519	US 1996-672150	19960627
				US 1995-373132 A2	19950117
	US 5536718	A	19960716	US 1995-373132	19950117
	CA 2258885	AA	19971231	CA 1997-2258885	19970620
				US 1996-672150 A	19960627
	WO 9749707	A1	19971231	WO 1997-US10736	19970620
	W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, GH, HU, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TR, TT, UA, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
				US 1996-672150 A	19960627
	AU 9734063	A1	19980114	AU 1997-34063	19970620
	AU 731925	B2	20010405		
				US 1996-672150 A	19960627
				WO 1997-US10736W	19970620
	EP 915876	A1	19990519	EP 1997-930167	19970620
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
				US 1996-672150 A	19960627
				WO 1997-US10736W	19970620
	BR 9710087	A	19990810	BR 1997-10087	19970620
				US 1996-672150 A	19960627
				WO 1997-US10736W	19970620
	CN 1231666	A	19991013	CN 1997-197413	19970620
				US 1996-672150 A	19960627
	JP 2000510154	T2	20000808	JP 1998-503379	19970620
				US 1996-672150 A	19960627
				WO 1997-US10736W	19970620
	NZ 332605	A	20000929	NZ 1997-332605	19970620
				US 1996-672150 A	19960627
	KR 2000022297	A	20000425	KR 1998-710719	19981228
				US 1996-672150 A	19960627

PATENT FAMILY INFORMATION:

FAN 1996:469927

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5536718	A	19960716	US 1995-373132	19950117
	US 5610156	A	19970311	US 1995-458210	19950602
				US 1995-373132 A3	19950117
	US 5612334	A	19970318	US 1995-460346	19950602
				US 1995-373132 A3	19950117
	ZA 9600297	A	19970715	ZA 1996-297	19960115
				US 1995-373132 A	19950117
	CA 2210631	AA	19960725	CA 1996-2210631	19960116
				US 1995-373132 A	19950117
	WO 9622293	A1	19960725	WO 1996-US1076	19960116
	W: AL, AM, AU, BB, BG, BR, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KP, KR, LK, LR, LT, LU, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, UZ, VN, AZ, BY, KG, KZ, RU, TJ, TM				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR,				

NE, SN, TD, TG

AU 9647698 A1 19960807
 AU 707982 B2 19990722

EP 804438 A1 19971105

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,
 SI, LT, LV

BR 9607182 A 19971111

CN 1198746 A 19981111
 CN 1065244 B 20010502

JP 11500106 T2 19990106

IL 116775 A1 19990817

TW 403752 B 20000901

US 5700796 A 19971223

US 5753648 A 19980519

FAN 1998:8260

PATENT NO. KIND DATE

PI US 5700796 A 19971223

US 5536718 A 19960716

WO 9749708 A1 19971231

W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, GH, HU, IL, IS,
 JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO,
 RU, SG, SI, SK, SL, TR, TT, UA, UZ, VN, YU, ZW, AM, AZ, BY, KG,
 KZ, MD, RU, TJ, TM

RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR,
 GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA,
 GN, ML, MR, NE, SN, TD, TG

AU 9736414 A1 19980114

US 1995-373132 A 19950117

AU 1996-47698 19960116

US 1995-373132 A 19950117

WO 1996-US1076 W 19960116

EP 1996-903698 19960116

US 1995-373132 A 19950117

WO 1996-US1076 W 19960116

BR 1996-7182 19960116

US 1995-373132 A 19950117

WO 1996-US1076 W 19960116

CN 1996-192641 19960116

US 1995-373132 A 19950117

JP 1996-522452 19960116

US 1995-373132 A 19950117

WO 1996-US1076 W 19960116

IL 1996-116775 19960116

US 1995-373132 A 19950117

TW 1996-85100461 19960116

US 1995-373132 A 19950117

US 1996-671442 19960627

US 1995-373132 A2 19950117

US 1996-672150 19960627

US 1995-373132 A2 19950117

APPLICATION NO. DATE

US 1996-671442 19960627

US 1995-373132 A2 19950117

US 1995-373132 19950117

WO 1997-US10755 19970620

US 1996-671442 A 19960627

AU 1997-36414 19970620

US 1996-671442 A 19960627

WO 1997-US10755W 19970620

FAN 1998:42402

PATENT NO. KIND DATE

PI WO 9749707 A1 19971231

W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, GH, HU, IL, IS,
 JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO,
 RU, SG, SI, SK, SL, TR, TT, UA, UZ, VN, YU, ZW, AM, AZ, BY, KG,
 KZ, MD, RU, TJ, TM

RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR,
 GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA,
 GN, ML, MR, NE, SN, TD, TG

WO 1997-US10736 19970620

US 1996-672150 A 19960627

US 5753648	A	19980519	US 1996-672150	19960627
AU 9734063	A1	19980114	US 1995-373132 A2	19950117
AU 731925	B2	20010405	AU 1997-34063	19970620
EP 915876	A1	19990519	US 1996-672150 A	19960627
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO			WO 1997-US10736W	19970620
			EP 1997-930167	19970620
BR 9710087	A	19990810	US 1996-672150 A	19960627
			WO 1997-US10736W	19970620
JP 2000510154	T2	20000808	BR 1997-10087	19970620
			US 1996-672150 A	19960627
			WO 1997-US10736W	19970620
			JP 1998-503379	19970620
			US 1996-672150 A	19960627
			WO 1997-US10736W	19970620


OS MARPAT 129:16148

IT **180416-70-0P 180416-71-1P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of tricyclic benzodiazepines as vasopressin antagonists)


RN 180416-70-0 CAPLUS

CN 3-Pyridinecarboxamide, 2-(methylamino)-N-[4-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-ylcarbonyl)phenyl] - (9CI) (CA INDEX NAME)




RN 180416-71-1 CAPLUS


CN 3-Pyridinecarboxamide, 2-[[3-(dimethylamino)propyl]amino]-N-[4-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-ylcarbonyl)phenyl] - (9CI) (CA INDEX NAME)



GI



I



II

AB Title compds. [I; D,E,F = N or (un)substituted CH; R1R2 = atoms to complete an(un)substituted (hetero)arom. ring; Y = bond, CH2, CH2CH2, CO, alkylidene; Z = (CH2)mNR3 or NR3(CH2)m; R3 = COZ1R6; R6 = acylamino, etc.; Z1 = (un)substituted 1,4-phenylene or -3,6-pyridinediyl; m = 1 or 2] were prepd. Thus, 1-(2-nitrobenzyl)pyrrole-2-carboxaldehyde (prepn. given) was reductively cyclized and the product N-acylated by 2-PhC6H4CONHC6H4(OMe)(CO2H)-3,4 (prepn. given) to give, after condensation with HCHO/CH2(NMe2)2, title compd. II. Data for biol. activity of I were given.

RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 13 OF 20 CAPLUS COPYRIGHT 2003 ACS

AN 1998:268489 CAPLUS

DN 128:321568

TI Anthranilic acid derivatives as multi drug resistance modulators

IN Ryder, Hamish; Ashworth, Philip Anthony; Roe, Michael John; Brumwell, Julie Elizabeth; Hunjan, Sukhjit; Folkes, Adrian John; Sanderson, Jason Terry; Williams, Susannah; Maximen, Levi Michael; et al.

PA Xenova Ltd., UK; Ryder, Hamish; Ashworth, Philip Anthony; Roe, Michael

John; Brumwell, Julie Elizabeth; Hunjan, Sukhjait; Folkes, Adrian John;
Sanderson, Jason Terry; Williams, Susannah; Maximen, Levi Michael

SO PCT Int. Appl., 203 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9817648	A1	19980430	WO 1997-GB2885	19971017
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
				WO 1996-GB2552 A	19961018
				GB 1997-17576 A	19970819
	AU 9746339	A1	19980515	AU 1997-46339	19971017
	AU 741922	B2	20011213		
				WO 1996-GB2552 A	19961018
				GB 1997-17576 A	19970819
				WO 1997-GB2885 W	19971017
	ZA 9709329	A	19990419	ZA 1997-9329	19971017
				WO 1996-GB2552 A	19961018
	EP 934276	A1	19990811	EP 1997-945030	19971017
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
				WO 1996-GB2552 W	19961018
				GB 1997-17576 A	19970819
				WO 1997-GB2885 W	19971017
	BR 9711935	A	19990824	BR 1997-11935	19971017
				WO 1996-GB2552 A	19961018
				GB 1997-17576 A	19970819
				WO 1997-GB2885 W	19971017
	GB 2334521	A1	19990825	GB 1999-8193	19971017
	GB 2334521	B2	20001004		
				WO 1996-GB2552 A	19961018
				GB 1997-17576 A	19970819
				WO 1997-GB2885 W	19971017
	CN 1241181	A	20000112	CN 1997-180708	19971017
				WO 1997-GB2885 W	19971017
	JP 2001502683	T2	20010227	JP 1998-519108	19971017
				WO 1996-GB2552 W	19961018
				GB 1997-17576 A	19970819
				WO 1997-GB2885 W	19971017
	RU 2195454	C2	20021227	RU 1999-109990	19971017
				WO 1996-GB2552 A	19961018
				GB 1997-17576 A	19970819
				WO 1997-GB2885 W	19971017
	BG 103327	A	20001130	BG 1999-103327	19990413
				WO 1996-GB2552 A	19961018
				GB 1997-17576 A	19970819
				WO 1997-GB2885 W	19971017
	NO 9901836	A	19990617	NO 1999-1836	19990416
				WO 1996-GB2552 A	19961018

			GB 1997-17576 A 19970819
			WO 1997-GB2885 W 19971017
KR 2000049278	A	20000725	KR 1999-703389 19990417
			WO 1996-GB2552 A 19961018
US 6218393	B1	20010417	GB 1997-17576 A 19970819
			US 1999-284642 19990609
			GB 1997-17576 A 19970819
HK 1019330	A1	20010112	WO 1997-GB2885 W 19971017
			HK 1999-103773 19990901
			WO 1996-GB2552 W 19961018
			GB 1997-17576 A 19970819
			WO 1997-GB2885 W 19971017


OS MARPAT 128:321568

IT 206872-39-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of anthranilic acid derivs. as multi-drug resistance modulators)

RN 206872-39-1 CAPLUS

CN 2-Quinoxalinecarboxamide, N-[3-[[[4-[2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]phenyl]amino]carbonyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Anthranilic acid derivs. I [R, R1, R2 = H, alkyl, OH, alkoxy, halo, NO2, amino; or R1R2 = OCH2O or OCH2CH2O; R3 = H, alkyl; R4 = alkyl, or CH2 or CH2CH2 bridged to either Ph ring; R5 = H, OH, alkyl; X = bond, O, S, S(CH2)p, O(CH2)p; p = 1-6; R6 = H, alkyl, alkoxy; q = 0 or 1; Ar = (un)satd. carbo- or heterocyclic; R7, R8 = H, (un)substituted alkyl, alkoxy, OH, halo, Ph, NHOH, NO2, amino, SH, alkylthio; or R7R8 = CH:CHCH:CH or OCH2O; n = 0, 1; m = 0-6] and their pharmaceutically acceptable salts are disclosed. The compds. are inhibitors of P-glycoprotein, and may thus be used, inter alia, as modulators of multidrug resistance in the treatment of multidrug-resistant cancers, for example, to potentiate the cytotoxicity of a cancer drug. For instance, amidation of 3-quinolinecarboxylic acid with the corresponding aminothiophene deriv. via the acid chloride gave title compd. II in 44% yield. In a test for potentiation of doxorubicin toxicity to AR 1.0

cells, II had a potentiation index of 142 at 30 nM.

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 14 OF 20 CAPLUS COPYRIGHT 2003 ACS
AN 1998:42402 CAPLUS
DN 128:114970
TI Preparation of tricyclic benzazepine as vasopressin antagonists
IN Albright, Jay Donald; Venkatesan, Aranapakam Mudumbai; Dusza, John Paul;
Sum, Fuk-wah
PA American Cyanamid Co., USA
SO PCT Int. Appl., 411 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 4

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9749707	A1	19971231	WO 1997-US10736	19970620
W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, GH, HU, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TR, TT, UA, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5753648	A	19980519	US 1996-672150 A	19960627
			US 1996-672150	19960627
			US 1995-373132 A2	19950117
AU 9734063	A1	19980114	AU 1997-34063	19970620
AU 731925	B2	20010405		
			US 1996-672150 A	19960627
			WO 1997-US10736W	19970620
EP 915876	A1	19990519	EP 1997-930167	19970620
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
			US 1996-672150 A	19960627
			WO 1997-US10736W	19970620
BR 9710087	A	19990810	BR 1997-10087	19970620
			US 1996-672150 A	19960627
			WO 1997-US10736W	19970620
JP 2000510154	T2	20000808	JP 1998-503379	19970620
			US 1996-672150 A	19960627
			WO 1997-US10736W	19970620

PATENT FAMILY INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5536718	A	19960716	US 1995-373132	19950117
US 5610156	A	19970311	US 1995-458210	19950602
			US 1995-373132 A3	19950117
US 5612334	A	19970318	US 1995-460346	19950602
			US 1995-373132 A3	19950117
ZA 9600297	A	19970715	ZA 1996-297	19960115
			US 1995-373132 A	19950117
CA 2210631	AA	19960725	CA 1996-2210631	19960116
			US 1995-373132 A	19950117
WO 9622293	A1	19960725	WO 1996-US1076	19960116

W: AL, AM, AU, BB, BG, BR, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG,
 KP, KR, LK, LR, LT, LU, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO,
 SG, SI, SK, TR, TT, UA, UZ, VN, AZ, BY, KG, KZ, RU, TJ, TM
 RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE,
 IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR,
 NE, SN, TD, TG

AU 9647698 A1 19960807 US 1995-373132 A 19950117
 AU 707982 B2 19990722 AU 1996-47698 19960116

US 1995-373132 A 19950117
 WO 1996-US1076 W 19960116
 EP 804438 A1 19971105 EP 1996-903698 19960116

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,
 SI, LT, LV

US 1995-373132 A 19950117
 WO 1996-US1076 W 19960116
 BR 9607182 A 19971111 BR 1996-7182 19960116
 US 1995-373132 A 19950117
 WO 1996-US1076 W 19960116
 CN 1198746 A 19981111 CN 1996-192641 19960116
 CN 1065244 B 20010502

US 1995-373132 A 19950117
 JP 11500106 T2 19990106 JP 1996-522452 19960116
 US 1995-373132 A 19950117
 WO 1996-US1076 W 19960116
 IL 116775 A1 19990817 IL 1996-116775 19960116
 US 1995-373132 A 19950117
 TW 403752 B 20000901 TW 1996-85100461 19960116
 US 1995-373132 A 19950117
 US 5700796 A 19971223 US 1996-671442 19960627
 US 1995-373132 A219950117
 US 5753648 A 19980519 US 1996-672150 19960627
 US 1995-373132 A219950117

FAN 1998:8260

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5700796	A	19971223	US 1996-671442	19960627
US 5536718	A	19960716	US 1995-373132 A219950117	
WO 9749708	A1	19971231	US 1995-373132	19950117
			WO 1997-US10755	19970620


W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, GH, HU, IL, IS,
 JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO,
 RU, SG, SI, SK, SL, TR, TT, UA, UZ, VN, YU, ZW, AM, AZ, BY, KG,
 KZ, MD, RU, TJ, TM
 RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR,
 GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA,
 GN, ML, MR, NE, SN, TD, TG

US 1996-671442 A 19960627
 AU 9736414 A1 19980114 AU 1997-36414 19970620
 US 1996-671442 A 19960627
 WO 1997-US10755W 19970620

FAN 1998:324820


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5753648	A	19980519	US 1996-672150	19960627
US 5536718	A	19960716	US 1995-373132 A219950117	
CA 2258885	AA	19971231	US 1995-373132	19950117
			CA 1997-2258885	19970620

WO 9749707 A1 19971231 US 1996-672150 A 19960627
WO 1997-US10736 19970620
W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, GH, HU, IL, IS,
JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO,
RU, SG, SI, SK, SL, TR, TT, UA, UZ, VN, YU, ZW, AM, AZ, BY, KG,
KZ, MD, RU, TJ, TM
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA,
GN, ML, MR, NE, SN, TD, TG
US 1996-672150 A 19960627
AU 9734063 A1 19980114 AU 1997-34063 19970620
AU 731925 B2 20010405
US 1996-672150 A 19960627
WO 1997-US10736W 19970620
EP 915876 A1 19990519 EP 1997-930167 19970620
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,
SI, LT, LV, FI, RO
US 1996-672150 A 19960627
WO 1997-US10736W 19970620
BR 9710087 A 19990810 BR 1997-10087 19970620
US 1996-672150 A 19960627
WO 1997-US10736W 19970620
CN 1231666 A 19991013 CN 1997-197413 19970620
US 1996-672150 A 19960627
JP 2000510154 T2 20000808 JP 1998-503379 19970620
US 1996-672150 A 19960627
WO 1997-US10736W 19970620
NZ 332605 A 20000929 NZ 1997-332605 19970620
US 1996-672150 A 19960627
KR 2000022297 A 20000425 KR 1998-710719 19981228
US 1996-672150 A 19960627
OS MARPAT 128:114970
IT **180416-70-0P 180416-71-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of tricyclic benzazepines as vasopressin antagonists)
RN 180416-70-0 CAPLUS
CN 3-Pyridinecarboxamide, 2-(methylamino)-N-[4-(5H-pyrrolo[2,1-
c][1,4]benzodiazepin-10(11H)-ylcarbonyl)phenyl] - (9CI) (CA INDEX NAME)





RN 180416-71-1 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[3-(dimethylamino)propyl]amino]-N-[4-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-ylcarbonyl)phenyl]- (9CI) (CA INDEX NAME)



GI



AB The title compds. I [AB = CH₂NR₃, R₃NCH₂; R₃ = (un)substituted arylcarbonyl; DEF ring = 5-member N-contg. (un)substituted heterocyclic ring; Y = .sigma.-bond, CH₂; R = alkyl, NH₂, halogen, etc; R₁ = alkyl, OH, Cl, OMe, etc.], which exhibit antagonist activity at V₁ and/or V₂ receptors and exhibit in vivo vasopressin antagonist activity would be useful in treating diseases characterized by excess renal reabsorption of water (e.g., brain edema, cirrhosis, hyponatremia, brain edema, congestive heart failure, etc.), are prepd. Thus, 2-chloro-4-[(4'-trifluoromethyl) [1,1'-biphenyl-2-carbonyl]amino]benzoyl chloride was reacted with 10,11-dihydro-5H-pyrrolo[2,1-c][1,4-]benzodiazepine, producing benzodiazepine II which demonstrated a rat kidney-derived V₁ receptor IC₅₀ of 41% at 1 .mu.M and 92% for the V₂ receptor at 10 .mu.M.

L4 ANSWER 15 OF 20 CAPLUS COPYRIGHT 2003 ACS

AN 1998:8260 CAPLUS

DN 128:88934

TI Preparation of tricyclic benzazepine vasopressin antagonists

IN Albright, Jay Donald; Venkatesan, Aranapakam M.; Dusza, John P.; Sum, Fuk-wah

PA American Cyanamid Co., USA

SO U.S., 64 pp., Cont.-in-part of U.S. 5,536,718.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5700796	A	19971223	US 1996-671442	19960627
				US 1995-373132 A2	19950117
	US 5536718	A	19960716	US 1995-373132	19950117
	WO 9749708	A1	19971231	WO 1997-US10755	19970620
	W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, GH, HU, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO,				

RU, SG, SI, SK, SL, TR, TT, UA, UZ, VN, YU, ZW, AM, AZ, BY, KG,
 KZ, MD, RU, TJ, TM
 RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR,
 GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA,
 GN, ML, MR, NE, SN, TD, TG

AU 9736414 A1 19980114 US 1996-671442 A 19960627
 AU 1997-36414 19970620
 US 1996-671442 A 19960627
 WO 1997-US10755W 19970620

PATENT FAMILY INFORMATION:

FAN 1996:469927

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5536718	A	19960716	US 1995-373132	19950117
	US 5610156	A	19970311	US 1995-458210	19950602
	US 5612334	A	19970318	US 1995-373132 A319950117	
	US 5612334	A	19970318	US 1995-460346	19950602
	ZA 9600297	A	19970715	US 1995-373132 A319950117	
	CA 2210631	AA	19960725	ZA 1996-297	19960115
	WO 9622293	A1	19960725	US 1995-373132 A 19950117	
	W: AL, AM, AU, BB, BG, BR, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG,			CA 1996-2210631	19960116
	KP, KR, LK, LR, LT, LU, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO,			US 1995-373132 A 19950117	
	SG, SI, SK, TR, TT, UA, UZ, VN, AZ, BY, KG, KZ, RU, TJ, TM			WO 1996-US1076	19960116
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE,				
	IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR,				
	NE, SN, TD, TG				
	AU 9647698	A1	19960807	US 1995-373132 A 19950117	
	AU 707982	B2	19990722	AU 1996-47698	19960116
	EP 804438	A1	19971105	US 1995-373132 A 19950117	
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,			WO 1996-US1076 W 19960116	
	SI, LT, LV			EP 1996-903698	19960116
	BR 9607182	A	19971111	US 1995-373132 A 19950117	
	CN 1198746	A	19981111	WO 1996-US1076 W 19960116	
	CN 1065244	B	20010502	BR 1996-7182	19960116
	JP 11500106	T2	19990106	US 1995-373132 A 19950117	
	IL 116775	A1	19990817	WO 1996-US1076 W 19960116	
	TW 403752	B	20000901	US 1995-373132 A 19950117	
	US 5700796	A	19971223	TW 1996-85100461	19960116
	US 5753648	A	19980519	US 1995-373132 A 19950117	
				US 1996-671442	19960627
				US 1995-373132 A219950117	
				US 1996-672150	19960627
				US 1995-373132 A219950117	

FAN 1998:42402

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

PI	WO 9749707	A1	19971231	WO 1997-US10736	19970620
	W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, GH, HU, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TR, TT, UA, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5753648	A	19980519	US 1996-672150 A	19960627
				US 1996-672150	19960627
	AU 9734063	A1	19980114	US 1995-373132 A2	19950117
	AU 731925	B2	20010405	AU 1997-34063	19970620
				US 1996-672150 A	19960627
				WO 1997-US10736W	19970620
	EP 915876	A1	19990519	EP 1997-930167	19970620
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
				US 1996-672150 A	19960627
	BR 9710087	A	19990810	WO 1997-US10736W	19970620
				BR 1997-10087	19970620
				US 1996-672150 A	19960627
	JP 2000510154	T2	20000808	WO 1997-US10736W	19970620
				JP 1998-503379	19970620
				US 1996-672150 A	19960627
				WO 1997-US10736W	19970620
FAN	1998:324820				
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5753648	A	19980519	US 1996-672150	19960627
	US 5536718	A	19960716	US 1995-373132 A2	19950117
	CA 2258885	AA	19971231	US 1995-373132	19950117
				CA 1997-2258885	19970620
	WO 9749707	A1	19971231	US 1996-672150 A	19960627
	W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, GH, HU, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TR, TT, UA, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			WO 1997-US10736	19970620
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9734063	A1	19980114	US 1996-672150 A	19960627
	AU 731925	B2	20010405	AU 1997-34063	19970620
				US 1996-672150 A	19960627
				WO 1997-US10736W	19970620
	EP 915876	A1	19990519	EP 1997-930167	19970620
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
				US 1996-672150 A	19960627
	BR 9710087	A	19990810	WO 1997-US10736W	19970620
				BR 1997-10087	19970620
				US 1996-672150 A	19960627
	CN 1231666	A	19991013	WO 1997-US10736W	19970620
				CN 1997-197413	19970620
				US 1996-672150 A	19960627

JP 2000510154	T2	20000808	JP 1998-503379	19970620
			US 1996-672150 A	19960627
			WO 1997-US10736W	19970620
NZ 332605	A	20000929	NZ 1997-332605	19970620
			US 1996-672150 A	19960627
KR 2000022297	A	20000425	KR 1998-710719	19981228
			US 1996-672150 A	19960627


OS MARPAT 128:88934

IT 180416-70-0P 180416-71-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of tricyclic benzazepine vasopressin antagonists)


RN 180416-70-0 CAPLUS

CN 3-Pyridinecarboxamide, 2-(methylamino)-N-[4-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-ylcarbonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 180416-71-1 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[3-(dimethylamino)propyl]amino]-N-[4-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-ylcarbonyl)phenyl]- (9CI) (CA INDEX NAME)



GI



AB The title compds. [I; Y = (CH₂)_n (n = 0-2), CH(C1-3 alkyl), C(O); AB = (CH₂)_mNR₃, NR₃(CH₂)_m (m = 1-2; R₃ = C(O)Ar; Ar = (un)substituted Ph, 3-pyridyl); Z with two carbon atoms attached = (un)substituted Ph, a 5-membered arom. heterocyclic ring having one heteroatom selected from O, N, S, a 6-membered arom. heterocyclic ring having one N atom, etc.; D, E, F = C, N], which exhibit antagonist activity at V1 and/or V2 receptors, in vivo vasopressin antagonist activity, and oxytocin antagonist activity, and are useful in treating diseases characterized by excess renal reabsorption of water, were prepd. Thus, treatment of 6-[(5-fluoro-2-methylbenzoyl)amino]pyridine-3-carboxylic acid with SOCl₂ followed by reaction of the resulting acid chloride with 10,11-dihydro-5H-pyrrolo[2,1-c][1,4]benzodiazepine afforded the title compd. II which showed IC₅₀ of 0.033 .mu.M against rat hepatic V1 receptors binding and IC₅₀ of 0.004 .mu.M against rat kidney medullary V2 receptors binding.

L4 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2003 ACS
 AN 1996:469927 CAPLUS
 DN 125:168035
 TI Preparation of tricyclic benzazepine vasopressin receptor antagonists
 IN Albright, Jay D.; Venkatesan, Aranapakam M.; Dusza, John P.; Sum, Fuk-Wah
 PA American Cyanamid Co., USA
 SO U.S., 71 pp.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5536718	A	19960716	US 1995-373132	19950117
	US 5610156	A	19970311	US 1995-458210	19950602
				US 1995-373132 A3	19950117
	US 5612334	A	19970318	US 1995-460346	19950602
				US 1995-373132 A3	19950117
	ZA 9600297	A	19970715	ZA 1996-297	19960115
				US 1995-373132 A	19950117
	CA 2210631	AA	19960725	CA 1996-2210631	19960116
				US 1995-373132 A	19950117
	WO 9622293	A1	19960725	WO 1996-US1076	19960116
	W: AL, AM, AU, BB, BG, BR, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KP, KR, LK, LR, LT, LU, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, UZ, VN, AZ, BY, KG, KZ, RU, TJ, TM				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
				US 1995-373132 A	19950117
	AU 9647698	A1	19960807	AU 1996-47698	19960116
	AU 707982	B2	19990722		
				US 1995-373132 A	19950117
				WO 1996-US1076 W	19960116
	EP 804438	A1	19971105	EP 1996-903698	19960116
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV				
				US 1995-373132 A	19950117
				WO 1996-US1076 W	19960116
	BR 9607182	A	19971111	BR 1996-7182	19960116
				US 1995-373132 A	19950117
				WO 1996-US1076 W	19960116
	CN 1198746	A	19981111	CN 1996-192641	19960116
	CN 1065244	B	20010502		
				US 1995-373132 A	19950117
	JP 11500106	T2	19990106	JP 1996-522452	19960116
				US 1995-373132 A	19950117
				WO 1996-US1076 W	19960116
	IL 116775	A1	19990817	IL 1996-116775	19960116
				US 1995-373132 A	19950117
	TW 403752	B	20000901	TW 1996-85100461	19960116
				US 1995-373132 A	19950117
	US 5700796	A	19971223	US 1996-671442	19960627
				US 1995-373132 A2	19950117
	US 5753648	A	19980519	US 1996-672150	19960627
				US 1995-373132 A2	19950117

PATENT FAMILY INFORMATION:

FAN	1998:8260				
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5700796	A	19971223	US 1996-671442	19960627
				US 1995-373132 A2	19950117
	US 5536718	A	19960716	US 1995-373132	19950117
	WO 9749708	A1	19971231	WO 1997-US10755	19970620
	W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, GH, HU, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TR, TT, UA, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
				US 1996-671442 A	19960627
	AU 9736414	A1	19980114	AU 1997-36414	19970620
				US 1996-671442 A	19960627
				WO 1997-US10755W	19970620
FAN	1998:42402				
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9749707	A1	19971231	WO 1997-US10736	19970620
	W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, GH, HU, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TR, TT, UA, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
				US 1996-672150 A	19960627
	US 5753648	A	19980519	US 1996-672150	19960627
				US 1995-373132 A2	19950117
	AU 9734063	A1	19980114	AU 1997-34063	19970620
	AU 731925	B2	20010405		
				US 1996-672150 A	19960627
				WO 1997-US10736W	19970620
	EP 915876	A1	19990519	EP 1997-930167	19970620
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
				US 1996-672150 A	19960627
				WO 1997-US10736W	19970620
	BR 9710087	A	19990810	BR 1997-10087	19970620
				US 1996-672150 A	19960627
				WO 1997-US10736W	19970620
	JP 2000510154	T2	20000808	JP 1998-503379	19970620
				US 1996-672150 A	19960627
				WO 1997-US10736W	19970620
FAN	1998:324820				
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5753648	A	19980519	US 1996-672150	19960627
				US 1995-373132 A2	19950117
	US 5536718	A	19960716	US 1995-373132	19950117
	CA 2258885	AA	19971231	CA 1997-2258885	19970620
				US 1996-672150 A	19960627
	WO 9749707	A1	19971231	WO 1997-US10736	19970620
	W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, GH, HU, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO,				

RU, SG, SI, SK, SL, TR, TT, UA, UZ, VN, YU, ZW, AM, AZ, BY, KG,
 KZ, MD, RU, TJ, TM
 RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR,
 GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA,
 GN, ML, MR, NE, SN, TD, TG

AU 9734063 A1 19980114 US 1996-672150 A 19960627
 AU 731925 B2 20010405 AU 1997-34063 19970620

US 1996-672150 A 19960627
 WO 1997-US10736W 19970620
 EP 915876 A1 19990519 EP 1997-930167 19970620

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,
 SI, LT, LV, FI, RO

US 1996-672150 A 19960627
 WO 1997-US10736W 19970620
 BR 9710087 A 19990810 BR 1997-10087 19970620

US 1996-672150 A 19960627
 WO 1997-US10736W 19970620
 CN 1231666 A 19991013 CN 1997-197413 19970620

US 1996-672150 A 19960627
 JP 2000510154 T2 20000808 JP 1998-503379 19970620

US 1996-672150 A 19960627
 WO 1997-US10736W 19970620
 NZ 332605 A 20000929 NZ 1997-332605 19970620

US 1996-672150 A 19960627
 KR 2000022297 A 20000425 KR 1998-710719 19981228

US 1996-672150 A 19960627


OS MARPAT 125:168035


IT 180416-70-0P 180416-71-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of tricyclic benzazepine vasopressin receptor antagonists)

RN 180416-70-0 CAPLUS


CN 3-Pyridinecarboxamide, 2-(methylamino)-N-[4-(5H-pyrrolo[2,1-
 c][1,4]benzodiazepin-10(11H)-ylcarbonyl)phenyl] - (9CI) (CA INDEX NAME)






RN 180416-71-1 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[3-(dimethylamino)propyl]amino]-N-[4-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-ylcarbonyl)phenyl] - (9CI) (CA INDEX NAME)



GI



AB The title compds. [I; Z = fused (un)substituted Ph ring; AB = CH₂NR₃, R₃NCH₂; R₃ = (un)substituted arylcarbonyl; DEF ring = 5-member N-contg. (un)substituted heterocyclic ring], which exhibit antagonist activity at V1 and/or V2 receptors and exhibit in-vivo vasopressin antagonist activity, useful in treating diseases characterized by excess renal reabsorption of water (e.g., brain edema, cirrhosis, hyponatremia, brain edema, congestive heart failure, etc.), are prepd. Thus, 2-chloro-4-[(4'-trifluoromethyl) [1,1'-biphenyl-2-carbonyl]amino]benzoyl chloride was reacted with 10,11-dihydro-5H-pyrrolo[2,1-c][1,4-]benzodiazepine, producing benzodiazepine II, which demonstrated a rat kidney-derived V1 receptor IC₅₀ of 41% at 1 .mu.M and 92% for the V2 receptor at 10 .mu.M.

L4 ANSWER 17 OF 20 CAPLUS COPYRIGHT 2003 ACS

AN 1994:298580 CAPLUS

DN 120:298580

TI Reactions of 5-(p-anisyl)-2-methyl-7-(p-tolyl)-4H-pyrido[2,3-d][1,3]oxazin-4-one

AU Madkour, Hassan M. F.; Salem, Mounir A. I.; Abdel-Rahman, Taha M.; Azab, Mohamed E.

CS Fac. Sci., Ain Shams Univ., Abbassia, Egypt

SO Heterocycles (1994), 38(1), 57-69

CODEN: HTCYAM; ISSN: 0385-5414

DT Journal

LA English

IT 154778-17-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 154778-17-3 CAPLUS

CN 3-Pyridinecarboxamide, 2-(acetyl-amino)-4-(4-methoxyphenyl)-N,6-bis(4-methylphenyl)- (9CI) (CA INDEX NAME)